Welcome

Dear Colleagues

The WHO ColIaborating Centre for Leishmaniasis at the Instituto de Salud Carlos III, Madrid and the Drugs for Neglected Diseases initiative, Geneva have joined efforts to co-organize the WorldLeish-6 Congress. On behalf of the WorldLeish Committee, it is a great pleasure and privilege to invite you to the WorldLeish-6 Congress to be held in Toledo, Spain, from 16 to 20 May 2017.

Previous WorldLeish Congresses have been held in Istanbul (1997), Crete (2001), Palermo (2005), Lucknow (2009), and Porto de Galinhas (2013). The Scientific Programme of the upcoming Congress will address issues ranging from molecules to disease control, with the patient as the main focus. The agenda will feature contemporary lectures, hot-topic sessions, and satellite symposia covering the latest developments on leishmaniasis. The educational programme of the Congress will strike a balance between the needs of basic research and clinical issues. We are taking great care in designing a programme that caters to young scientists through fostering scientific exchange, presentations, awards, and social activities.

The cultural programme also promises to be appealing, and will highlight Toledo's fascinating culture and history. Successively a Roman municipality, the capital of the Visigoth Kingdom, a fortress of the Umayyad Emirate of Cordoba, and once the capital of Spain under the Emperor Charles V, Toledo is unique. In 1986, Toledo was made a World Heritage City by UNESCO. The city has made remarkable contributions to humankind, namely, the Councils between the IV and VIII centuries with definitive implications for the history of Spain and Europe; the creation and work of the Toledo School of Translators in the XII and XIII centuries, opening Europe to the values of the Neo-Plato Aristotelianism, and hosted the dramatic and expressionistic paintings of El Greco (Crete,1541-Toledo, 1614).
The Spanish hospitality and cuisine are even more remarkable in the city of Toledo, which is Spain’s gastronomic capital of for 2016. Its close proximity to Madrid facilitates access from the international airport, but also provides many opportunities for pre- or post-congress visits to the capital. Other UNESCO World Heritage cities like Avila, Segovia, Cuenca, or Salamanca are less than 200 km from Toledo. The brand new ‘El Greco Congress Conference Centre’ has all modern facilities and is five minutes from the historical landmarks of Toledo. More than 4000 rooms in all category hotels are at a walking distance to the congress centre, most hotels offer a friendly environment for socializing in the evenings.

The School of Translators was not created by chance: for more than two centuries, Toledo offered an environment of peaceful coexistence among Christians, Muslims, and Jews, attracting intellectuals that made the city flourish. Since then, Toledo became known as ‘the city of three cultures’, and the title remains to this day. Next year Toledo will continue in this spirit as, with the WorldLeish-6 Congress humbly contributing to a better world by providing an international forum for sharing scientific values, knowledge, and research for the benefit of patients around the world. Indeed, during WorldLeish-6, Toledo will be true to its multicultural spirit of knowledge and understanding.

Once again, on behalf of the Instituto de Salud Carlos III, the Drugs for Neglected Diseases initiative and of the Organizing Committee, we would like to invite you to WorldLeish-6 Congress. We sincerely believe that you will enjoy both the scientific and cultural aspects of the programme, and the pleasure of springtime in Toledo.

We look forward to personally welcoming you to Toledo in May, 2017!

Jorge Alvar (chair) & Javier Moreno (co-chair)

PROGRAMME


To see more detailed information about the speakers, please click on the session title
Room Room Room Room
Plenary talk
08:30-09:30
Registration
P Session 1
09:30-11:00
Welcome
Inaugural lecture
11:00-11:30 Coffee Break
P Session 2
11:30-13:00
1 Expression and signal transduction in leishmaniasis 2 The present and future of VL treatment 3 Epidemiology
and control:
biological inputs
Oral Communications ►
13:00-14:00 Lunch
P Session 3
14:00 - 15:30
4 Gene regulation and new methods for gene and genome editing  5 PKDL 6 operational research
15:00 – 16:30 Oral Communications ►
16:30 – 19:30 Poster Presentation
Satellite Symposium
16:00-17:30
Landscape of the Spanish Research in Leishmaniasis
Supported by Marca España and sponsored by
 
17:30 - 18:00 Coffee Break Award to NTD Drug Discovery Booster Consortium
Satellite Symposium
18:00-19:30
  TCAKS, a publicly available box of chemical compounds:
case study of multilateral collaboration to combat leishmaniasis and trypanosomiasis

Special meetings
16:00 - 19:30
Closed sessions
18:00 - 18:30 Award to NTD Drug Discovery Booster consortium
20:15 Welcome Concert. The Battle of the Organs (at the Cathedral of Toledo)

Opening Conference:

“A global journey of half a century with Leishmania and Leishmaniasis”

Farrokh Modabber. Former WHO/TDR

Parallel session 1

(1) Expression and signal transduction in leishmaniasis

Chair Gérald Spath. Institut Pasteur, Paris, France

Co-chair Miguel A. Morales. Notre Dame Univ. Indiana



1.1 Transcriptome profiling of Leishmania mexicana life cycle stages.
Eva Gluenz.University of Oxford, UK

1.2 New insights into Leishmania donovani stage-specific expression and phosphorylation using a systems-level approach.
Gerald Späth. Institut Pasteur/INSERM U1201, Paris, France

1.3 A network of cap-binding proteins and their interacting partners modulate adaptation to different stress conditions in Leishmania.
Michal Shapira. Ben Gurion University of the Negev, Beer Sheva, Israel

1.4 Integrated analysis of the transcriptome of Leishmania donovani and macrophage host cell upon infection with antimony-resistant and antimony–sensitive strains.
Geraldine De Muylder. Institute of Tropical Medicine, Antwerp, Belgium

Parallel session 1

(2) The present and future of VL treatment

Chair Fabiana Alves. DNDi, Geneva, Switzerland

Co-chair Ahmed Musa. Institute of Endemic Diseases, University Khartoum, Sudan



2.1 Treatment of VL: the African case.
Robert Kimutai, DNDi, Nairobi, Kenya

2.2 Current knowledge and needs for VL treatment in Brazil.
Gustavo Romero, Universidad de Brasilia, Brazil

2.3 New insights into the exposure-response relationships for miltefosine in the treatment for VL.
Thomas Dorlo, The Netherlands Cancer Institute, Amsterdam, Netherlands

2.4 Perspectives for improved treatments on VL.
Fabiana Alves, DNDi, Geneva, Switzerland

Parallel session 1

(3) Leishmaniasis epidemiology and control: biological inputs

Chair Caryn Bern. University of California, San Francisco, USA

Co-chair Orin Courtenay. University of Warwick, Coventry, UK



3.1 Why biological understanding of reservoir and vector is essential to understanding epidemiology and developing control strategies
Caryn Bern. University of California, San Francisco, USA

3.2 Leishmania in the sand fly and determinants of infectivity of sand fly bite and subsequent pathology.
Matthew Rogers. London School of Hygiene and Tropical Medicine, London, UK

3.3 Experimental models of parameters of transmission between sand fly and host
Nathan Peters. University of Calgary, Alberta, Canada

Parallel session 2

(4) Gene regulation and new methods for gene and genome editing

Chair Steve Beverley. University of Saint Louis, Missouri, USA

Co-chair Rafael Balaña. Universidad de Leon, Leon, Spain



4.1 RNA-binding proteins as major regulators of the Leishmania response to intracellular stress and amastigote differentiation.
Barbara Papadopoulou. University Laval, Quebec, Canada

4.2 Dominant positive and dominant negative genomic screens for drug resistance studies in Leishmania.
Marc Ouellete. University Laval, Quebec, Canada

4.3 Ribosome profiling.
Peter J. Myler. Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, USA

4.4 Direct sequencing of Leishmania genome in biological samples.
JC Dujardin. Institute of Tropical Medicine, Antwerp, Belgium

Parallel session 2

(5) PKDL

Chair Ed Zijlstra. DNDi, Geneva, Switzerland

Co-chair Shyam Sundar. Varanasi University, India



5.1 PKDL an overview of clinical aspects.
Ahmed Musa. Institut of Endemic Diseases, University of Khartoum, Sudan

5.2 Special forms of PKDL.
Venkatesh Ramesh. Safdarjung Hospital, New Delhi, India

5.3 Advances in understanding of immunobiology of PKDL.
Poonam Salotra. Indian Council of Medical Research, New Delhi, India

5.4 PKDL insights in transmission.
Dinesh Mondal. ICDDRB, Dhaka, Bangladesh

Parallel session 2

(6) Operational Research

Chair Marleen Boelaert, Institut Tropical Medicine, Antwerp, Belgium

Co-chair Axel Kroeger. TDR/WHO, Liverpool School of Tropical Medicine, UK



6.1 Reaching the elimination target in the state of Vaishali,
Bihar, India. Pradeep Das. Rajendra Memorial Research Institute, India

6.2 Risk factors for VL and predictors of relapse after treatment in VL.
Dinesh Mondal. ICDDRB, Dhaka, Bangladesh

6.3 Cost-effectiveness analysis of introducing new diagnostics for cutaneous leishmaniasis.
Celine Aerts. IS Global, Barcelona, Spain

6.4 Cross-sectional surveys in Bangladesh, India, Ethiopia and Sudan to understand visceral leishmaniasis treatment seeking, diagnosis, treatment and household economic burden. Vikas Aggarwal. Kalacore. Noida, India

SATELLITE SYMPOSIA

Landscape of the Spanish Research in Leishmaniasis

Supported by Marca España and sponsored by RICET and SEMTSI
Tuesday May 16th, 16:00-17:30
Chair: Luis Rivas, CSIC
Co-chair: Jorge Alvar, DNDi

• Applied research at the WHO Collaborating Center of Leishmaniasis, a 20 years endeavor.
Javier Moreno, ISCIII
• Basic research at the CSIC.
Dolores González Pacanowska. IPB-CSIC
• Clinical research & international cooperation.
Nines Lima. MSF-Spain
• Canine leishmaniosis research at the University.
Guadalupe Miró. UCM

TCAKS, a publicly available box of chemical compounds: case study of multilateral collaboration to combat leishmaniasis and trypanosomiasis

Sponsored by Tres Cantos Open Lab Foundation and Collaborative Drug Discovery
Tuesday May 16th, 18:00-19:30

Chair: Julio Martín.
Director, Biology Head of Kinetoplastid DPU (DDW). GSK Spain

• Welcome and intro to the symposium. Julio Martín. GSK&TCOLF
• GSK, how you get the KinetoBoxes. Albane Kessler. GSK
• CDD, a data repository ready for sharing. Mariana Vaschetto. CDD
• Experience sharing: listening to the voice of Kineto Boxes requesters
• Flash presentations by CSIC/Madrid, ITM/Antwerp, Institute Pasteur/Paris, CRCHU/Quebec
• Round Table and Q&A

The Battle of the organs

1.- Tiento A II. J.B.J Cabanilles

Baptiste-Florian Marle-Ovrard. Organ of the Emperor (16-18 centuries)
Pablo Márquez Caraballo: Berdalonga Organ
Atsuko Takano: Echevarría Organ
Juan José Montero: Organ of the Tabernacle Chapel.

2.-Concert for two organs.Bach-Vivaldi.

Allegro Adagio Allegro.
Pablo Márquez Caraballo and Atsuko Nakano:
Berlandonga and Echevarría organs

3.-Organ Concerto Op 4 nº 5 in F major HVW 293. G. F. Haendel

Larghetto Alla Siciliana Presto.
Baptiste-Florian Marle-Ovrard and Juan Jose Montero:
“Realejo” organs. (Historical positive organs)

4.-Charles III entrance. Improvisation.

Pablo Márquez Caraballo: Emperor’s organ.

5.- Jonah and the Whale

Sailing to Tarshish
Storm and sacrifice.
Rescue of Jonah by the whale

Baptiste-Florian Marle-Ovrard: Emperor´s organ.
Juan José Montero: Echevarria organ
Patrizia Salvani: Organ of the Tabernacle Chapel.

6.-The Princess Galiana (Improvisation)

Baptiste-Florian Marle-Ovrard: Berdalonga: organ.

7.-Concerto in C minor, BWV 1060. J. S. Bach

Allegro Adagio Allegro.
Pablo Márquez Caraballo, Atsuko Takano and Juan José Montero. Realejo organs

8.-Sonata in A minor. C. Ph. E. Bach

Atsuko Takano:Organ of the Tabernacle Chapel.

9.-Tiento 7th tono in A-la-mi-re mode. J. B. J. Cabanilles

Pablo Márquez Caraballo: Emperor´s organ
Baptiste-Florian Marle-Ovrard: Berdalonga organ.
Juan José Montero: Echevarría organ
Atsuko Takano: Organ of the Tabernacle Chapel.

10.-Battle of St. Quentin (Improvisation on “Veni Creator”)

Pablo Márquez Caraballo: Emperor´s organ.
Baptiste-Florian Marle-Ovrard: Berdalonga organ.
Juan José Montero: Echevarría organ.
Atsuko Takano: Organ of the Tabernacle Chapel

Plenary 1

Parasite genetic manipulsation; understanding how Leishmania kills and how to kill Leishmania

Jeremy Mottram. University of York, York, UK

Parallel session 1

(7) Molecular retooling in macrophage–parasite interactions

Chair Barbara Papadopoulou. University of Laval, Québec, Canada

Co-chair José María Requena. Universidad Autónoma Madrid, Madrid. Spain



7.1 The signaling pathway that initiate Leishmania differentiation.
Dan Zilberstein, Technion Institute, Haifa, Israel

7.2 Phagosome remodelling by Leishmania.
Albert Descoteaux. Centre INRS-Institut Armand Frappier, Laval, Canada

7.3 Leishmania iron acquisition and utilization within host macrophages.
Norma Andrews. University of Maryland, Maryland, USA

7.4 Leishmania uses mincle to target an inhibitory itam signaling pathway in dendritic cells that dampens adaptive immunity to infection.
Salvador Iborra, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain

(8) Non-invasive field adapted tools (and biomarkers) for VL diagnosis and test of cure

Chair Israel Cruz. FIND, Geneva, Switzerland

Co-chair Anabela Cordeiro. Universidade do Porto, Porto, Portugal



8.1 Challenges and progress toward a simple point of care diagnostic test for Visceral Leishmaniasis in East Africa.
Maowia Mukhtar. Institute of Endemic Diseases, University of Khartoum, Sudan

8.2 RDTs and diagnostic algorithms in the management of persistent fever syndrome in VL endemic areas.
François Chappuis. University of Geneva, Geneva, Switzerland

8.3 Development of prognostic serological biomarkers for visceral leishmaniasis and their relevance to disease control.
Michael Miles. London School of Hygiene and Tropical Medicine, London, UK

8.4: The diagnostic challenges and needs in the kala-azar elimination programme in South Asia.
Suman Rijal. DNDi, India

(9) Tools to understand the epidemiology of leishmaniasis and asymptomatic infection

Chair Selma Jerónimo. Universidad Federal do Rio Grande du Norte, Brazil

Co-chair Charles Jaffe. Hebrew University Jerusalem, Jerusalem, Israel


9.1 Biomarkers of infection and disease.
Eugenia Carrillo. ISCIII, Madrid, Spain

9.2 Xenodiagnosis and proxies for infectiousness.
Shyam Sundar. Varanasi University, India

9.3 Leishmanin skin testing versus interferon gamma release assays.
Edgar Carvalho. Universidade Federal da Bahía and FIOCRUZ, Salvador de Bahía, Brazil

9.4 Leishmanin skin testing versus interferon gamma release assays in visceral leishmaniasis patients.
Selma Jerónimo. Universidad Federal do Rio Grande du Norte, Brazil

Parallel session 2

(10) Myeloids subsets in the macrophage-leishmania outcome

Chair David Sacks. NIAID, Bethesda, USA

Co-chair Manuel Fresno. Centro de Biología Molecular CSIC, Madrid, Spain



10.1 Neutrophil functions in Leishmaniasis
Elvira Saraiva. Federal University Rio de Janeiro, Brazil

10.2 The role of M2 dermal macrophages in the pathogenesis of chronic cutaneous leishmaniasis.
David Sacks. NIAID, Bethesda, USA

10.3 Dendritic cell subsets in Leishmaniasis.
Esther von Stebut, University of Mainz, Mainz, Germany

10.4 Inflammatory monocytes play a critical role in pathogenesis of visceral leishmaniasis.
Abhay Satoskar, Ohio State University, Ohio, USA

Parallel session 2

(11) Immunosuppression and leishmaniasis

Chair Carlos Costa. Universidade Federal do Piauí, Teresina, Brazil

Co-chair Hannah Akuffo. Karolinska Institute, Stockholm, Sweden



11.1 HIV-VL co-infection in Africa.
Johan Van Griesven Institute of Tropical Medicine, Antwerp, Belgium

11.2 HIV-VL co-infection in Asia.
Sakib Burza, MSF Spain

11.3 Solid organ transplants and leishmaniasis.
Javier Moreno, ISCIII, Spain

11.4 Malnutrition and leishmaniasis.
Mercè Herrero. WHO, Geneva, Switzerland

(12) Sand fly-Leishmania interactions

Chair Shaden Kamhawi. NIH, Rockville, USA

Co-chair Petr Volf. Charles University, Prague, Czech Republic



12.1 Sand fly midgut microbiota augments virulence of leishmaniasis
Shaden Kamhawi

12.2 New parasites and new vectors.
Paul Bates. Lancaster University, Lancaster, UK

12.3 Sand fly transmitted Leishmania exosomes: impact on cutaneous leishmaniasis.
Martin Olivier. McGill University, Montreal, Canada

12.4 From metacyclics to retromonds: A new stage in Leishmania development within the sand fly midgut impacts vectorial capacity.
Jesús Valenzuela. NIH, Rocksville, USA

Parallel session 3

(13) Microbiome and nanobiome in relation to Leishmania

Chair Nicolas Fasel. Université de Lausanne, Lausanne, Switzerland

Co-chair Yara Traub-Cesko. Instituto Oswaldo Cruz-Fiocruz, Rio de Janeiro, Brazil



13.1 Microbiome, antimicrobial peptides and Leishmania inside the sand fly.
Yara Traub-Cseko. Instituto Oswaldo Cruz-Fiocruz, Rio de Janeiro, Brazil

13.2 Leishmania-Phlebovirus co-infections in sand flies, dogs, and humans. Elyes Zhioua. Institut Pasteur, Tunis, Tunisia

13.3 The Leishmania virome and its role in disease severity.
Stephen Beverly. Washington University, St Louis, USA

13.4 Leishmania, innate immunity and microbiome interface as leitmotiv for leishmanicidal compounds.
Luis Rivas. Centro de Investigaciones Biológicas, CSIC, Madrid, Spain

(14) VL Drug discovery

Chair Charles Mowbray. DNDi, Geneva, Switzerland
Co-chair Mitsuyuki Shimada. Takeda

14.1 The A to Z of drug discovery for visceral leishmaniasis. Kevin Read. Drug Discovery Unit.
Dundee University, Dundee, UK

14.2 Kinetoboxes: the beginning of a beautiful friendship
María Marco-Martín. GlaxoSmithKline, Madrid, Spain

14.3 Novel antileishmanial agents: amino-pyrazole ureas with potent in vitro and in vivo activity
Paul A. Glossop. Sandexis

14.4 Discovery and optimisation of a new class of potent antileishmanial compounds and determination of their mechanism of action.
Frantisek Supek. Genomics Institute of the Novartis Research Foundation, San Diego, US

(15) Outbreak assessment & surveillance

Chair Piero Olliaro. WHO/TDR, Geneva, Switzerland
Co-chair Suman Rijal. DNDi, India

15.1 New estimates of leishmaniasis incidence in selected high burden countries.
José Antonio Ruiz Postigo. WHO, Geneva, Switzerland

15.2 Re-emergence and outbreaks of VL.
Koert Ritmeijer. Médecins Sans Frontières

15.3 Early warning systems.
Iván Vélez. PECET-Universidad de Antioquia, Medellín, Colombia

15.4 Tools for rapid assessment of VL outbreaks.
Mercè Herrero. WHO, Geneva, Switzerland

SATELLITE SYMPOSIA

“An overview of thermotherapy for the treatment of cutaneous leishmaniasis”

Sponsored by Thermosurgery technologies
Wednesday May 17th, 16:00-18:00
Chair: Abhay Satoskar
• Introduction and Overview of thermotherapy. Gena Zischke
• Efficacy of Thermotherapy to Treat Cutaneous Leishmaniasis: A Meta-Analysis of Controlled Clinical Trials.
Ivan D. Velez
• Title to be defined
Dr Bumb
• Treatment of displaced populations or in conflict areas.
Dr. Safi
• The Immunology of a Healing Response in Cutaneous Leishmaniasis Treated with Localized Heat therapy.
Ines Elakhal Naouar and Naomi Aronson
• Thermotherapy plus Miltefosine for the treatment of cutaneous leishmaniasis.
Byron Arana

SATELLITE SYMPOSIA

“Major issues in Vector Control”

Organized and sponsored by WL6, Inesfly and Mundo Sano.
Wednesday May 17th , 18:00-19:30

Chair: Rajib Chowdhury. National Institute of Preventive and Social Medicine (NIPSOM), Bangladesh.
Co-chair Michael Coleman, LSTM, Liverpool, UK

• Insecticide resistance in sand flies.
Michael Coleman. LSTM, Liverpool, UK
• Challenges in vector control for the kala-azar elimination and post-elimination era in India.
Sridhar Srikantiah, CARE, India
• Eco-epidemiology and GIS. Daniel Oscar Salomón. Instituto Nacional de Medicina Tropical,
Puerto Iguazú, Argentina
• Climate-change & land use. Guy Hendrickx, Avia GIS, Belgium
• Inesfly, an innovative method for sand fly control
Debashis Gosh, Bangladesh

SATELLITE SYMPOSIA

Milestones achieved in the treatment of Visceral Leishmaniasis

Sponsored by Gilead

Wednesday May 17th, 16:00-17:30

Plenary 2

Can VL be eliminated in the Indian subcontinent?

Conducted by Daniel Argaw. WHO, Geneva, Switzerland

Panelists:

• M. Boelaert. Institute of Tropical Medicine, Antwerp, Belgium
• M. Jamsheed. WHO/SEARO, New Delhi, India
• A.C. Dhariwal. Ministry of Health and Family Welfare, New Delhi, India
• A. Be-Nazir. NIPSON, Dhaka, Bangladesh
• C. Bern. University of California, San Francisco, USA

Parallel session 1

(16) T cells response in the protection and pathology of leishmaniasis

Chair Edgar Carvalho. Universidade Federal da Bahía and FIOCRUZ, Salvador de Bahía, Brazil

Co-chair Paul Kaye. University of York, York, UK



16.1 Leishmania-neutrophil crosstalk impacts  the T cell response.
Fabienne Tacchini-Cottier. University of Lausanne, Switzerland

16.2 Interactions between Leishmania and cells of innate and adaptive immune responses.
Claudia Brodskyn. FIOCRUZ, Salvador de Bahia, Brazil

16.3 Identification of protective Leishmania-specific CD4+ T cells: implications for vaccine design and vaccination strategies against leishmaniasis.
Jude Uzonna. University of Manitoba, Winnipeg, Canada

16.4 IL-17 is associated with protection in human visceral leishmaniasis.
Om Prakash Singh. Banaras Hindu University, Varanasi, India

(17) Diagnosis of dermal leishmaniasis, limitations and challenges

Chair Elisa Cupolillo. Instituto Oswaldo Cruz, Rio de Janeiro, Brazil

Co-chair Israel Cruz. FIND, Geneva, Switzerland



17.1 Exploiting the human anti-alpha-Gal response for the diagnosis of Old World cutaneous leishmaniasis.
Alvaro Acosta Serrano. Liverpool School of Tropical Medicine and Hygiene, Liverpool, UK

17.2 Role of molecular tools in clinical management of cutaneous leishmaniasis: diagnosis, species identification and parasite quantification.
Elisa Cupolillo. Instituto Oswaldo Cruz, Rio de Janeiro, Brazil

17.3 Evaluation of PoC tests for CL diagnosis in Afghanistan.
Israel Cruz. FIND, Geneva, Switzerland

17.4 Minimally invasive microbiopsies: a novel sampling method for identifying asymptomatic potentially infectious carriers of Leishmania donovani.
Oscar Kirstein. Hebrew University of Jerusalem, Israel

(18) New vector control measures

Chair Dia Elnaiem. University of Maryland, Maryland, USA

Co-chair Alexandra Chaskopoulou. USDA-ARS European Biological Control Lab, Thessaloniki, Greece



18.1 Experimental strategies for intercepting sand flies to prevent them from reaching and entering homes.
Alon Warburg. Hebrew University of Jerusalem, Israel

18.2 A new approach in the control of Lutzomya longipalpis s.l. in Brazil Reginaldo Brazil.
IOC-Fiocruz, Rio de Janeiro, Brazil

18.3 Novel methods of control of visceral leishmaniasis vectors in East Africa.
Dia Elnaiem. University of Maryland, Maryland, USA

18.4 Integrated vector management for the control of wild sand fly populations associated with animal facilities.
Alexandra Chaskopoulou.USDA-ARS European Biological Control Lab, Thessaloniki, Greece

Parallel session 2

(19) Molecular basis on virulence and tropism

Chair David Sacks. NIH, Bethesda, USA

Co-chair Jean Claude Dujardin. Institute of Tropical Medicine, Antwerp, Belgium

19.1 Probing the strategies of antimony resistant Leishmania donovani to induce aggressive infection
Syamal Roy, Indian Institute of Chemical Biology, Kolkata, India

19.2 Metastatic leishmaniasis.
Nicolas Fasel. University of Lausanne, Switzerland

19.3 The genetic basis for the natural attenuation of Leishmania donovani
Greg Matlashewski. McGill University, Montreal, Canada

19.4 Immune deviation in human leishmaniasis
David Mosser. University of Maryland, Maryland, USA

(20) CL treatment and pipeline drugs

Chair Max Grögl. U.S. Naval Medical Research Unit No. 6, Lima, Peru

Co-chair Olga Zerpa. Emerson Clinical Research Insitute, Washington, USA

20.1 Current recommendations for treating CL worldwide.
Afif Bensalah. Arabian Golf Univeristy, Bahrein

20.2 CL treatment: clinical developments.
Byron Arana. DNDI, Geneva, Switzerland

20.3 CL R&D pipeline.
Charles Mowbray. DNDI, Geneva, Switzerland

20.4 Harmonised clinical trial methodologies for CL.
Piero Olliaro. WHO/TDR, Geneva, Switzerland

(21) What´s new on reservoirs?

Chair Jeffrey Shaw. Universidade de Sao Paulo, Sao Paulo, Brazil

Co-chair Luigi Gradoni. Instituto Superiore di Sanitá, Roma, Italy

21.1 Updates on reservoirs of American leishmaniasis.
André Roque. Instituto Oswaldo Cruz, Rio de Janeiro, Brazil

21.2 The role of bats as reservoirs of leishmaniasis.
Cáris Maroni Nunes. Faculty of Veterinary Medicine, Araçatuba, São Paulo, Brazil

21.3 Potential reservoirs in Mediterranean leishmaniasis.
Ezio Ferroglio. University of Turin, Italy

21.4 Is Tarim hare a reservoir of desert-type visceral leishmaniasis in Taklamakan basin,
Xinjiang, China, KP Chang. Rosalint Franklin University, Chicago, USA

Parallel session 3

(22) Advances in Immunopathology

Chair Nancy Saravia. CIDEIM, Cali, Colombia

Co-chair Ali Mohammadian Mohammad Hussein. Institut Pasteur, Teheran, Iran

22.1 Pathways involved in the outcome of Leishmania infantum infection.
Selma Jeronimo. Universidad Federal do Rio Grande du Norte, Brazil

22.2 Cytotoxic CD8 T cells in the pathology of leishmaniasis.
Philip Scott. University of Pennsylvania, Philadelphia, USA

22.3 Neutrophil phenotypes in human leishmaniasis.
Mary Wilson. University of Iowa, Iowa, USA

22.4 Leishmania RNA virus-1 is equally distributed among severe and non-severe phenotypes in a prospective cohort of American tegumentary leishmaniasis. Braulio Mark Valencia. Institute of Tropical Medicine Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru

(23) Physical methods and natural (phyto) products for CL treatment

Chair: Naomi Aronson. Uniformed Services University, Bethesda, USA

Co-Chair: Sara Robledo. Universidad de Antioquia, Medellin, Colombia

23.1 Thermotherapy in the treatment of CL.
Naomi Aronson. Uniformed Services University, Bethesda, USA

23.2 Clinical experience using cryotherapy for CL.
Ali Khamesipour. Insitut Pasteur, Teheran, Iran

23.3 Evaluation of the antileishmanial effects of natural products (plants) extracts.
Antonia Franco. Instituto Nacional de Pesquisas da Amazônia, Manaos, Brazil

23.4 Clinical experience using herbal medicine for CL.
Farhad Handjani. Shiraz University, Iran

(24) WHO control Programmes

Chair José Antonio Ruiz Postigo. WHO, Geneva, Switzerland

Co-chair Elkhan Gasimov. WHO/EURO, Copenhagen, Denmark

24.1 Structure, achievements and challenges in leishmaniasis control in the WHO African region. Abate Mulugueta. WHO/AFRO, Addis Ababa, Ethiopia

24.2 East Mediterranean region.
Albis Gabrielli. WHO/EMRO, Cairo, Egypt

24.3 Leishmaniasis control programme in the WHO European region.
Elkhan Gasimov. WHO/EURO, Copenhagen, Denmark

24.4 Epidemiological analysis of deaths by visceral leishmaniasis in the Americas: challenges for public health.
Ana Nilce ElKhouri. WHO/PAHO, Rio de Janeiro, Brazil

"Cutaneous Leishmaniasis prevention, diagnosis and management: existing and future tools”

Sponsored by Sanofi
Thursday May 18th, 16:00-17:30

Co-chairs:
• Pierre Buffet. Institut National de Transfusion Sanguine, France
• Karim Aoun. Institut Pasteur de Tunis, Tunisia
WHO and PAHO: Overview of available tools for training
• Jose Antonio Ruiz Postigo. WHO, Switzerland
Behavior change communication through a comic book in schools in Tunisia’s endemic areas
• Aida Bouratbine. Institut Pasteur de Tunis, Tunisia
Newly available support for medical education
• Pierre Buffet. Institut National de Transfusion Sanguine, France
An app to aid diagnosis of Leishmaniasis in endemic areas in Colombia
• Luisa Rubiano, Centro Internacional de Entrenamiento e investigaciones médicas, Colombia

How to communicate better in leishmaniasis

Organized by Mundo Sano and DNDi and sponsored by Mundo Sano.
Thursday May 18th, 18:00-19:30
Expected Outcome: to deliver an article that could be disseminated in the different journals just before the congress.

Chair: Irene Tato, Mundo Sano
Co-chair:Jean François Alesandrini, DNDi

• Emilio de Benito, El País Chair of ANIS, Spanish Association of Health Journalists
• Antonio Calvo Roy. Chair of the AECC, Spanish Association of Scientific Communicators
• Talha Burki, The Lancet
• Verah Okeyo, Daily Nation (Kenya)
• Nora Bär, La Nación
• Franziska Badenschier, European Union of Science Journalists Associations (EUSJA), Germany

CONSENSUS SYMPOSIA

Route Map for Cutaneous Leishmaniasis drugs

Conducted by Simon Croft, London School of Hygiene and Tropical Medicineand
and Byron Arana, DNDi
Panelists: to be defined
Over the past decade there has been progress in the treatment and pre-clinical development of drugs for visceral leishmaniasis. In contrast, many parts of R & D for cutaneous leishmaniasis have been left behind. One part of the CL pathway has received attention, namely the design and analysis of clinical trials. But where are the new drugs to enter the clinical trials?
This session will focus on potential routes to take new drugs and treatments from discovery to clinical trials. It will examine the relevance and use of assays and models for evaluation, the value of PK PD analysis, systemic and topical formulations, and roles for immunomodulatory, combinations and re-purposing. Regulatory issues will also be considered.
Outcomes will include (i) a consensus document for publication and (ii) an understanding by participants of how better to work together to bring new drugs forward.

Plenary 3

Conflict and leishmaniasis

Conducted by Koert Ritmeijer. Médecins Sans Frontières

Panelists:

• I. Vélez. PECET, Medellín, Colombia

• Mounir Lado. IMA World Health, Juba, South Sudan

• T. Burki. The Lancet

• Alice Cowley. Mentor, UK

Parallel session 1

(25) Population genetics and molecular epidemiology

Chair Jenefer Blackwell. Cambridge University, UK

Co-chair Israel Cruz. FIND, Geneva, Switzerland



25.1 Genome-wide studies of genetic risk factors for human leishmaniasis. Jenefer M Blackwell. Cambridge University, UK

25.2 Genomics of L. donovani and drug resistance: the roles of cryptic genome diversity. Hideo Imamura. Institute of Tropical Medicine, Antwerp, Belgium

25.3 Comparative analysis of genetically and phenotypically variable Leishmania donovani hybrids allows to explore their capacity for adaptative evolution. Evi Gouzelou. Institut Pasteur International Network, Paris, France

25.4 Systematics and population genetics of phlebotomine sand flies and their consequences on the epidemiology of the leishmaniases. Jérôme Depaquit. Université de Reims Champagne Ardenne, Reims, France

(26) Advances in Immunotherapy

Chair Farrokh Modabber. Former WHO/TDR

Co-chair Abhay Satoskar. Ohio State University, Ohio, USA



26.1 Host directed therapy. Chris Engwerda. QIMR Berghofer Medical Research Institut, Brisbane, Australia

26.2 RNA vaccines. Steve Reed. IDRI, Seattle, USA

26.3 CpG ODN for immunotherapy in CL. Daniela Verthelyi. FDA, Betehesda, USA

26. 4 Targets for immunotherapy of leishmaniasis. Diane MacMahon-Pratt. Yale University, New Haven, USA

(27) Quantitative studies of Leishmaniasis transmission and control

Chair Orin Courtenay. University of Warwick, UK

Co-chair Sake de Vlas. Erasmus University, Rotterdam, Netherlands



27.1 Longitudinal study of transmission in households with visceral leishmaniasis, asymptomatic infections and PKDL in Bihar, India. Greg Matlashewski. McGill University, Montreal, Canada

27.2 Spatial clustering of visceral leishmaniasis, asymptomatic infection and PKDL in Bangladesh. Lloyd Chapman, University of Warwick, UK

27.3 Community coverage with insecticide-impregnated dog collars protects against human clinical VL in NW Iran. Orin Courtenay. University of Warwick, UK

27.4 Elimination of visceral leishmaniasis on the indian subcontinent: a comparison of predictions from three transmission models. Epke Le Rutte. Erasmus MC, University Medical Center Rotterdam, The Netherlands

Parallel session 2

(28) Bioimaging

Chair Geneviève Milon. Institut Pasteur, Paris, France

Co-chair Silvia Uliana. Universidade de Sao Paulo, Brazil



28.1 A drug discovery platform against visceral leishmaniasis, moving forward in vivo preclinical models Rosa M. Reguera. Universidad de León, León, Spain

28.2 Imaging to better understand host-parasite interaction. Lynette Beattie, University of Queensland, Australia

28.3 Measuring leishmania growth and physiology in vivo at the single cell level using imaging mass spectrometry. Malcolm McConville. University of Melbourne, Melbourne, Australia

(29) MCL and DCL

Chair Alejandro Llanos-Cuentas. Universidad Cayetano Heredia, Lima, Peru

Co-chair Felix Tapia. Universidad Central, Caracas, Venezuela



29.1 Host determinants in the outcome of treatment of dermal leishmaniasis. María Adelaida Gómez. CIDEIM, Cali, Colombia

29.2 Clinical Characteristics and Treatment Options for MCL, DCL and DL patients. Paulo Roberto Lima Machado. Fundação de Medicina Tropical do Amazonas, Manaus, Brazil

29.3 The natural history of Leishmania (Viannia) infection: metastasis and persistent infection. Nancy Saravia. CIDEIM, Cali, Colombia

29.4 Immunological mechanisms of MCL and DCL. Felix Tapia. Universidad Central, Caracas, Venezuela

(30) Leishmaniasis vaccine pipeline

Chair Javier Moreno. ISCIII, Madrid, Spain

Co-chair Hira Nakhasi. FDA, Bethesda, USA



30.1 Killed vaccines. Ali Khamesipour. Institute Pasteur, Teheran, Iran

30.2 Vaccines that promote CD8+ T cell responses. Paul Kaye. University of York, York, UK

30.3 From mouse to man: development of a candidate visceral leishmaniasis vaccine. Rhea Coler. IDRI, Seattle, USA

30.4 Live attenuated vaccines for leishmaniasis. Hira Nakhasi. FDA, Bethesda, USA

Parallel session 3

(31) Delivery systems for drugs and vaccines

Chair Ijeoma Uchegbu. Nanomerics Ltd, UK

Co-Chair Anabela Cordeiro. Universidade do Porto, Porto, Portugal



31.1 Translational studies - pharmacological beneficial organ targeting via the oral route Ijeoma Uchegbu. Nanomerics Ltd, UK

31.2 Anti microbial peptide based immunotherapy: various approaches to control leishmaniasis. Sima Rafati. Institute Pasteur, Iran

31.3 Virosomal platform as delivery system for leishmaniasis vaccine. Epifanio Fichera. Ednabiotech, Catania, Italy

(32) Drug Resistance

Chair Alicia Ponte Sucre. Universidad Central de Venezuela, Caracas, Venezuela

Co-chair Barbara Papadopoulou. University Laval, Québec, Canada



32.1 What are we talking about when we mention resistance? Rogelio López-Vélez. Hospital Universitario Ramón y Cajal, Madrid, Spain

32.2 Resistance to drug combination therapy in Leishmania. Francisco Gamarro. Instituto de Parasitología y Biomedicina López-Neyra, Granada, Spain

32.3 Molecular epidemiology of Leishmania donovani: the many roads to drug resistance. Jean-Claude Dujardin. Institute of Tropical Medicine, Antwerp, Belgium

32.4 The molecular basis of amphotericin B resistance in Leishmania. Michael Barrett. Roslyn Institute, Glasgow, UK

(33) Canine leishmaniosis: where do we stand?

Chair Bruno Travi. University of Texas Medical Branch, Galveston, USA

Co-chair Francisco Rojo. Universidad de Leon, Leon, Spain



33.1 The utility of Rapid Diagnostic Tests in the clinic and in the field.
Bruno Travi. University of Texas Medical Branch, Galveston, USA

33.2 The impact of treatment on dog infectiousness.
Guadalupe Miró. Universidad Complutense de Madrid, Madrid, Spain

33.3 Are prevention and control strategies working?
Filipe Dantas-Torres. Aggeu Magalhães Research Centre-FIOCRUZ, Recife, Brazil

33.4 New marker for the diagnosis of visceral leishmaniosis in asymptomatic dogs.
Anabela Cordeiro. Universidade do Porto, Porto, Portugal

Research in Leishmania vaccines

Sponsored by Leti

Friday May 19th, 16:00-17:30
• Ribosomal proteins for a human leishmaniasis pan vaccine: beyond Protein Q. Marta Román. LETI
• Toll like receptors (TLR) in canine leishmaniosis: role in disease and use on prevention. Laia Solano. Universidad Autónoma Barcelona
• Safety Multicenter post authorization pilot study on LetiFend, the new recombinant vaccine against canine leishmaniosis. Guadalupe Miró. Universidad Complutense Madrid

Fuenlabrada outbreak

Sponsored by Dirección General de Salud Publica Comunidad de Madrid and Colegio Oficial de Veterinarios de Madrid
Friday May 19th, 18:00-19:30
Chair Juan Martínez Hernández. Director General de Salud Pública de la Comunidad de Madrid
Co-chair Richard Ashford, Former Professor at Liverpool School of Tropical Medicine, UK
• Epidemiological aspect of the outbreak. María Ordobás. Servicio de Epidemiología, Comunidad de Madrid.
• Clinical aspects. Juan Victor San Martin. Hospital Universitario Fuenlabrada, Madrid, Spain
• Sand fly and reservoir studies. Ricardo Molina ISCIII, Madrid, Spain
• Environmental control actions. Jesús Carpintero Hervás. Consejería de Medio Ambiente, Administración local y Ordenación del territorio, Comunidad de Madrid, Spain
• Final remarks and presentation of the book “Brote de leishmaniasis en Fuenlabrada y otros municipios de la Comunidad de Madrid: el papel de las liebres y los conejos como resevorios”. Felipe Vilas. Dirección General de Salud Pública. Comunidad de Madrid

CS 2 Advocating for the future

Conducted by Jorge Alvar, chair of Worldleish 6

• Minister of Health of Colombia

• Ministers of Health from several endemic countries to be confirmed

• Mercedes Tatay, International Medical Secretary of Médecins Sans Frontières

• Bernard Pécoul, Executive director, DNDi
Room Room Room Room
Plenary Talk
08:30-09:30
Access to Treatment
Satellite Symposium 08:30-10:00 LeishVet Symposium sponsored by
     
P Session 1
09:30-11:00
34 Challenges on Implementation and Development of Clinical Trials 35 Students and masters talking out of the box Oral Communications ► 36 Platforms for Research & Control
Coffee Break
Satellite Symposium
10:30-12:00
LeishVet Symposium sponsored by
     
11:00-11:30 Coffee Break
11:30-12:00 Awards
12:00-12:45 Closure lecture
12:45-13:15 Closing remarks

Access to treatment

Conducted by Margriet den Boer, Médecins Sans Frontières

Panelists:
• B. Pécoul. DNDi, Geneva, Switzerland
• R. Sebbag Former Vice President Access to Medicines, Sanofi-Aventis
• JA Ruiz-Postigo. WHO/Leishmaniasis programme, Geneva, Switzerland
• Nirmal Kumar Ganguly. Visiting professor of eminence Translational Health Science & Technology Institute NCR Biotech Science Cluster, Faridabad, India

Parallel session 1

(34) Challenges on implementation and development of clinical trials

Chair Nathalie Strub-Wourgaft. DNDi, Geneva, Switzerland

Co-chair Jane Mbuy. KEMRI, Nairobi Kenya



34.1 Methodology and study design.
Vishal Goyal. DNDI, India

34.2 Good clinical practices.
Varalakshmi Elango. Former WHO/TDR

34.3 From clinical trials to access.
Nathalie Strub-Wourgaft. DNDi, Geneva, Switzerland

34.4 Progress of approval of clinical trials.

(35) STUDENTS AND MASTERS TALKING OUT OF THE BOX


Conducted by Graeme Bilbe, DNDi Geneva and Steve Reed, IDRI-Seattle
Panelists:
Rob Davidson, Northwick Park Hospital, London

Caryn Bern, California University

Franziska Badenschier. European Union of Science Journalists´Associations, Germany

(36) Platforms for research and control

Chair Monique Wasunna. DNDi, Nairobi, Kenya

Co-chair Jorge Alvar. DNDi, Geneva, Switzerland



36.1 The Lesihmaniasis East African Platform: contributing to strengthening clinical trial capacity, treatment and control of visceral leishmaniasis in Eastern Africa. Asrat Hailu. University of Addis Ababa, Addis Ababa, Ethiopia

36.2 Leishmaniasis research network (RedLeish): experience in Latin America. Joelle Rode. DNDi, Rio de Janeiro, Brazil

36.3 Building a joint effort to optimally assess the efficacy of visceral leishmaniasis therapies: a VL data repository and network. Philippe Guerin. Oxford University, Oxford, UK

36.4 Kalacore-Bi regional support for the control and elimination of visceral leishmaniasis in Africa and Asia: developing an integrated approach to implementation and research. Simon Croft. London School of Hygiene and Tropical Medicine, London, UK

9-10- LeishVet

Sponsored by Bayer

Double symposium. Saturday May 20th, 8:30-12:00

Chair: Jorge Alvar, DNDi Geneva, Switzerland

Co-chair: Guadalupe Miró, Universidad Complutense Madrid, Spain



  • Introduction to the Symposium and to LeishVet. Guadalupe Miró
  • Benefits of a One Health approach to leishmaniosis. Michael Day. University of Bristol, UK
  • Canine leishmaniosis in South America and in the Mediterranean basin (including other species of Leishmania infecting dogs). Luis Cardoso. Universidade de Trás-os-Montes e Alto Douro, Vila Real, Portugal
  • Emergence of canine leishmaniosis in new regions; is development in non-endemic areas a risk? Patrick Bourdeau. Ecole Nationale Vétérinaire, Agroalimentaire et de l´Alimentation, Nantes-Atlantique (ONIRIS), Nantes, France
  • Canine immunity to Leishmania infection: moving towards successful immunotherapy. Christine Petersen. University of Iowa, College of Public Health, USA
  • Lessons learned regarding feline leishmaniosis over the last decade (including gaps in knowledge). Maria Grazia Pennisi. Università di Messina, Messina, Italy


  • Chair Guadalupe Miró

    Co-chair Gad Baneth, Hebrew University, Rehovot, Israel

  • Diagnostic approaches to canine leishmaniosis in the era of vaccines. Laia Solano-Gallego. Universidad Autónoma de Barcelona
  • Current drug therapy and resistance in canine leishmaniosis. Gad Baneth
  • Use of immunosuppressive drugs in Leishmania infected dogs: how to minimize risks. Lluis Ferrer. Tufts Cummings School of Veterinary Medicine, Massachusets, USA
  • Vaccines against canine leishmaniosis – advantages and pitfalls. Gaetano Oliva. Università di Napoli, Napoli, Italy
  • Best canine leishmaniosis prevention strategies/measures in different settings. Guadalupe Miró
  • Closing conference: “War and peace: health indicators”

    Alejandro Gaviria. Minister of Health Colombia

    Awards:

    Tributes:

    Prof CP Thakur

    Prof AM El Hassan
    To see more detailed information about the speakers, please click on the session title

    PROGRAMME

    08:30-09:30 Registration


    09:30-10:00 Welcome ceremony


    10:00-11:00 Inaugural conference

    “A global journey of half a century with Leishmania and Leishmaniasis”
    Farrokh Modabber. Former WHO/TDR

    11:00-11:30 Coffee break

    11:30-13:00 Parallel sessions

    Auditorium
    (1) Expression and signal transduction in leishmaniasis
    Chair Gérald Spath. Institut Pasteur, Paris, France
    Co-chair Miguel A. Morales. Notre Dame Univ. Indiana

    1.1 Transcriptome profiling of Leishmania mexicana life cycle stages. Eva Gluenz.University of Oxford, UK

    1.2 New insights into Leishmania donovani stage-specific expression and phosphorylation using a systems-level approach. Gerald Späth. Institut Pasteur/INSERM U1201, Paris,France

    1.3 A network of cap-binding proteins and their interacting partners modulate adaptation to different stress conditions in Leishmania. Michal Shapira. Ben Gurion University of the Negev, Beer Sheva, Israel

    1.4 Integrated analysis of the transcriptome of Leishmania donovani and macrophage host cell upon infection with antimony-resistant and antimony–sensitive strains. Geraldine De Muylder. Institute of Tropical Medicine, Antwerp, Belgium


    Toledo room
    (2) PKDL ANTES ERA SESIÓN 5
    Chair Ed Zijlstra. DNDi, Geneva, Switzerland
    Co-chair Shyam Sundar. Varanasi University, India

    2.1 PKDL an overview of clinical aspects. Ahmed Musa. Institut of Endemic Diseases, University of Khartoum, Sudan

    2.2 Special forms of PKDL.Venkatesh Ramesh. Safdarjung hospital,New Delhi, India

    2.3 Advances in understanding of immunobiology of PKDL. Poonam Salotra. Indian Council of Medical Research, New Delhi, India

    2.4 PKDL insights in transmission. Dinesh Mondal. ICDDRB, Dhaka, Bangladesh


    Greco room C1-C2
    (3) Leishmaniasis epidemiology and control: biological inputs
    Chair Caryn Bern. University of California, San Francisco, USA
    Co-chair Orin Courtenay. University of Warwick, Coventry, UK

    3.1 Why biological understanding of reservoir and vector is essential to understanding epidemiology and developing control strategies Caryn Bern. University of California, San Francisco, USA

    3.2 Leishmania in the sand fly and determinants of infectivity of sand fly bite and subsequent pathology. Matthew Rogers. London School of Hygiene and Tropical Medicine, London, UK

    3.3 Experimental models of parameters of transmission between sand fly and host Nathan Peters. University of Calgary, Alberta, Canada

    11:30-13:00 Oral communications sessions

    Greco room D1-D2
    Oral communications session 1
    Chair Carmen Gil
    Co-chair Manuel Carlos López?

    Miradero room
    Oral communications session 2
    Chair ?
    Co-chair Antonio Osuna?

    13:00-14:00 Lunch break


    14:00-15:30 Parallel sessions

    Auditorium
    (4) Gene regulation and new methods for gene and genome editing
    Chair Steve Beverley. University of Saint Louis, Missouri, USA
    Co-chair Rafael Balaña. Universidad de Leon, Leon, Spain

    4.1 RNA-binding proteins as major regulators of the Leishmania response to intracellular stress and amastigote differentiation. Barbara Papadopoulou. University Laval, Quebec, Canada

    4.2 Dominant positive and dominant negative genomic screens for drug
    resistance studies in Leishmania. Marc Ouellete. University Laval, Quebec, Canada

    4.3 Ribosome profiling. Peter J. Myler. Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, USA

    4.4 Direct sequencing of Leishmania genome in biological samples. JC Dujardin. Institute of Tropical Medicine, Antwerp, Belgium

    Toledo room
    (5) The present and future of VL treatment ANTES ERA SESIÓN 2
    Chair Fabiana Alves. DNDi, Geneva, Switzerland
    Co-chair Ahmed Musa. Institute of Endemic Diseases, University Khartoum, Sudan

    5.1 Treatment of VL: the African case. Robert Kimutai, DNDi, Nairobi, Kenya

    5.2 Current knowledge and needs for VL treatment in Brazil. Gustavo Romero, Universidad de Brasilia, Brasil

    5.3 New insights into the exposure-response relationships for miltefosine in the treatment for VL. Thomas Dorlo, The Netherlands Cancer Institute, Amsterdam, Netherlands

    5.4 Perspectives for improved treatments on VL. Fabiana Alves, DNDi, Geneva, Switzerland

    Greco room C1-C2
    (6) Operational Research
    Chair Marleen Boelaert, Institut Tropical Medicine, Aantwerp, Belgium
    Co-chair Axel Kroeger. TDR/WHO, Liverpool School of Tropical Medicine, UK

    6.1 Reaching the elimination target in the state of Vaishali, Bihar, India. Pradeep Das. Rajendra Memorial Research Institute, India

    6.2 Risk factors for VL and predictors of relapse after treatment in VL. Dinesh Mondal. ICDDRB, Dhaka, Bangladesh

    6.3 Cost-effectiveness analysis of introducing new diagnostics for cutaneous leishmaniasis. Celine Aerts. IS Global, Barcelona, Spain

    6.4 Cross-sectional surveys in Bangladesh, India, Ethiopia and Sudan to understand visceral leishmaniasis treatment seeking, diagnosis, treatment and household economic burden. Vikas Aggarwal. Kalacore. Noida, India

    15:00-16:30 Oral communications sessions

    Greco room D1-D2
    Oral communications session 3
    Chair Carmen Thomas
    Co-chair Dan Zilberstein

    Miradero room (15:00-16:00)
    Oral communications session 4
    Chair Jorge Arévalo
    Co-chair Poonam Salotra

    15:30-17:00 Oral communications sessions

    Greco room C1-C2
    Oral communications session 5
    Chair Severine Blesson
    Co-chair Sakib Burza?

    16:00-17:30 Satellite simposium

    Auditorium
    “Landscape of the Spanish Research in Leishmaniasis”
    Supported by Marca España and sponsored by RICET and SEMTSI
    Chair: Luis Rivas, CSIC
    Co-chair: Jorge Alvar, DNDi
    · Applied research at the WHO Collaborating Center of Leishmaniasis, a 20 years endeavor. Javier Moreno, ISCIII
    · Basic research at the CSIC. Dolores González Pacanowska. IPB-CSIC
    · Clinical research & international cooperation. Nines Lima. MSF-Spain
    · Canine leishmaniosis research at the University. Guadalupe Miró. UCM

    17:30-18:00 Coffee break
    Greco room C2: Drug Booster Project awards

    18:00-19:30 Satellite simposium

    Toledo room
    "TCAKS, a publicly available box of chemical compounds: case study of multilateral collaboration to combat leishmaniasis and trypanosomiasis”
    Sponsored by Tres Cantos Open Lab Foundation and Collaborative Drug Discovery
    Chair: Julio Martín. Director, Biology Head of Kinetoplastid DPU (DDW). GSK Spain
    · Welcome and intro to the symposium. Julio Martín. GSK&TCOLF
    · GSK, how you get the KinetoBoxes. Albane Kessler. GSK
    · CDD, a data repository ready for sharing. Mariana Vaschetto. CDD
    · Experience sharing: listening to the voice of Kineto Boxes requesters
    · Flash presentations by CSIC/Madrid, ITM/Antwerp, Institute Pasteur/Paris, CRCHU/Quebec
    · Round Table and Q&A

    16:30-19:30 Poster presentations
    Topics
    1- Molecular and cell biology
    2- Host parasite cellular and molecular interactions
    3- Genetics, taxonomy and omics. Tools and reverse genetics
    11- Vector biology and leishmania-sand fly interactions

    20:15 Welcome concert
    The Battle of the organs
    Toledo Cathedral



    WEDNESDAY MAY 17TH


    08:30-09:30 Plenary session 1

    Auditorium
    Parasite genetic manipulation; understanding how Leishmania kills and how to kill Leishmania

    Jeremy Mottram. University of York, York, UK


    09:30-11:00 Parallel sessions

    Auditorium
    (7) Molecular retooling in macrophage–parasite interactions
    Chair Barbara Papadopoulou. University of Laval, Québec, Canada
    Co-chair José María Requena. Universidad Autónoma Madrid, Madrid. Spain

    7.1 The signaling pathway that initiate Leishmania differentiation. Dan Zilberstein, Technion Institute, Haifa, Israel

    7.2 Phagosome remodelling by Leishmania. Albert Descoteaux. Centre INRS-Institut Armand Frappier, Laval, Canada

    7.3 Leishmania iron acquisition and utilization within host macrophages. Norma Andrews. University of Maryland, Maryland, USA

    7.4 Leishmania uses mincle to target an inhibitory itam signaling pathway in dendritic cells that dampens adaptive immunity to infection. Salvador Iborra, Fundación Centro Nacional deInvestigaciones Cardiovasculares Carlos III, Madrid, Spain

    Toledo room
    (8) Non-invasive field adapted tools (and biomarkers) for VL diagnosis and test of cure
    Chair Israel Cruz. FIND, Geneva, Switzerland
    Co-chair Anabela Cordeiro. Universidade do Porto, Porto, Portugal

    8.1 Challenges and progress toward a simple point of care diagnostic test for Visceral Leishmaniasis in East Africa. Maowia Mukhtar. Institute of Endemic Diseases, University of Khartoum, Sudan

    8.2 RDTs and diagnostic algorithms in the management of persistent fever syndrome in VL endemic areas. François Chappuis. University of Geneva, Geneva, Switzerland

    8.3 Development of prognostic serological biomarkers for visceral leishmaniasis and their relevance to disease control. Michael Miles. LondonSchool of Hygiene and Tropical Medicine, London, UK

    8.4: The diagnostic challenges and needs in the kala-azar elimination programme in South Asia. Suman Rijal. DNDi, India

    Greco room C1-C2
    (9) Tools to understand the epidemiology of leishmaniasis and asymptomatic infection
    Chair Selma Jerónimo. Universidad Federal do Rio Grande du Norte, Brazil
    Co-chair Charles Jaffe. Hebrew University Jerusalem, Jerusalem, Israel

    9.1 Biomarkers of infection and disease. Eugenia Carrillo. ISCIII, Madrid, Spain

    9.2 Xenodiagnosis and proxies for infectiousness. Shyam Sundar. Varanasi University, India

    9.3 Leishmanin skin testing versus interferon gamma release assays. Edgar Carvalho. Universidade Federal da Bahía and FIOCRUZ, Salvador de Bahía, Brazil

    9.4 Leishmanin skin testing versus interferon gamma release assays in visceral leishmaniasis patients. Selma Jerónimo. Universidad Federal do Rio Grande du Norte, Brazil

    09:30-11:00 Oral communications sessions

    Greco room D1-D2
    Oral communications session 6
    Chair Vicente Larraga
    Co-chair Alexis Mendoza

    Miradero room
    Oral communications session 7
    Chair Basilio Valladares
    Co-chair Hechmi Louzir?


    11:00-11:30 Coffee break

    11:30-13:00 Parallel sessions

    Auditorium
    (10) Myeloid subsets in the macrophage-leishmania outcome
    Chair David Sacks. NIAID, Bethesda, USA
    Co-chair Manuel Fresno. Centro de Biología Molecular CSIC, Madrid, Spain

    10.1 Neutrophil functions in Leishmaniasis Elvira Saraiva. Federal University Rio de Janeiro, Brazil

    10.2 The role of M2 dermal macrophages in the pathogenesis of chronic cutaneous leishmaniasis. David Sacks. NIAID, Bethesda, USA

    10.3 Dendritic cell subsets in Leishmaniasis. Esther von Stebut, University of Mainz, Mainz, Germany

    10.4 Inflammatory monocytes play a critical role in pathogenesis of visceral leishmaniasis. Abhay Satoskar, Ohio State University, Ohio, USA

    Toledo room
    (11) Immunosuppression and leishmaniasis
    Chair Carlos Costa. Universidade Federal do Piauí, Teresina, Brazil
    Co-chair Hannah Akuffo. Karolinska Institute, Stockholm, Sweden

    11.1 HIV-VL co-infection in Africa. Johan Van Griesven Institute of Tropical Medicine, Antwerp, Belgium

    11.2 HIV-VL co-infection in Asia. Sakib Burza, MSF Spain

    11.3 Solid organ transplants and leishmaniasis. Javier Moreno, ISCIII, Spain

    11.4 Malnutrition and leishmaniasis. Mercè Herrero. WHO, Geneva, Switzerland

    Greco room C1-C2
    (12) Sand fly-Leishmania interactions
    Chair Shaden Kamhawi. NIH, Rockville, USA
    Co-chair Petr Volf. Charles University, Prague, Czech Republic

    12.1 Sand fly midgut microbiota augments virulence of leishmaniasis Shaden Kamhawi

    12.2 New parasites and new vectors. Paul Bates. Lancaster University, Lancaster, UK

    12.3 Sand fly transmitted Leishmania exosomes: impact on cutaneous leishmaniasis. Martin Olivier. McGill University, Montreal, Canada

    12.4 From metacyclics to retromonds: A new stage in Leishmania development
    within the sand fly midgut impacts vectorial capacity. Jesús Valenzuela. NIH, Rocksville, USA

    11:30-13:00 Oral communications sessions

    Greco room D1-D2
    Oral communications session 8
    Chair Lynn Soong
    Co-chair Manuel Segovia?

    Miradero room
    Oral communications session 9
    Chair ?
    Co-chair Jose María Pérez-Victoria

    13:00-14:00 Lunch break

    14:00-15:30 Parallel sessions

    Auditorium
    (13) Microbiome and nanobiome in relation to Leishmania
    Chair Nicolas Fasel. Université de Lausanne, Lausanne, Switzerland
    Co-chair Yara Traub-Cesko. Instituto Oswaldo Cruz-Fiocruz, Rio de Janeiro, Brazil

    13.1 Microbiome, antimicrobial peptides and Leishmania inside the sand fly. Yara Traub-Cseko. Instituto Oswaldo Cruz-Fiocruz, Rio de Janeiro,Brazil

    13.2 Leishmania-Phlebovirus co-infections in sand flies, dogs, and humans.
    Elyes Zhioua. Institut Pasteur, Tunis, Tunisia

    13.3 The Leishmania virome and its role in disease severity. Stephen Beverly. Washington University, St Louis, USA

    13.4 Leishmania, innate immunity and microbiome interface as leitmotiv for leishmanicidal compounds. Luis Rivas. Centro de Investigaciones Biológicas, CSIC, Madrid, Spain

    Toledo room
    (14) VL Drug discovery
    Chair Charles Mowbray. DNDi, Geneva, Switzerland
    Co-chair Mitsuyuki Shimada. Takeda

    14.1 The A to Z of drug discovery for visceral leishmaniasis. Kevin Read. Drug Discovery Unit. Dundee University, Dundee, UK

    14.2 Kinetoboxes: the beginning of a beautiful friendship
    María Marco-Martín. GlaxoSmithKline, Madrid, Spain

    14.3 Novel antileishmanial agents: amino-pyrazole ureas with potent in vitro and in vivo activity Paul A. Glossop. Sandexis

    14.4 Discovery and optimisation of a new class of potent antileishmanial compounds and determination of their mechanism of action. Frantisek Supek. Genomics Institute of the Novartis Research Foundation, San Diego, US

    Greco room C1-C2
    (15) Outbreak assessment & surveillance
    Chair Piero Olliaro. WHO/TDR, Geneva, Switzerland
    Co-chair Suman Rijal. DNDi, India

    15.1 New estimates of leishmaniasis incidence in selected high burden countries. José Antonio Ruiz Postigo. WHO, Geneva, Switzerland

    15.2 Re-emergence and outbreaks of VL. Koert Ritmeijer. Médecins Sans Frontières

    15.3 Early warning systems. Iván Vélez. PECET-Universidad de Antioquia, Medellín, Colombia

    15.4 Tools for rapid assessment of VL outbreaks. Mercè Herrero. WHO, Geneva, Switzerland

    15:00-16:30 Oral communications sessions

    Greco room D1-D2
    Oral communications session 10
    Chair Pascale Kropf
    Co-chair Louis Maes?

    Miradero room (15:00-16:00)
    Oral communications session 11
    Chair Gabriela Delgado?
    Co-chair Ana Margarita Montalvo

    15:30-17:00 Oral communications sessions

    Greco room C1-C2
    Oral communications session 12
    Chair Charles Jaffe
    Co-chair Luigi Gradoni

    16:00-18:00 Satellite simposium

    Auditorium
    “An overview of thermotherapy for the treatment of cutaneous leishmaniasis”
    Sponsored by Thermosurgery technologies
    Chair: Abhay Satoskar
    · Introduction and Overview of thermotherapy. Gena Zischke
    · Efficacy of Thermotherapy to Treat Cutaneous Leishmaniasis: A Meta-Analysis of Controlled Clinical Trials. Ivan D. Velez
    · Title to be defined Dr Bumb
    · Treatment of displaced populations or in conflict areas. Dr. Safi
    · The Immunology of a Healing Response in Cutaneous Leishmaniasis Treated with Localized Heat therapy. Ines Elakhal Naouar and Naomi Aronson
    · Thermotherapy plus Miltefosine for the treatment of cutaneous leishmaniasis. Byron Arana

    16:00-17:30 Satellite simposium

    Toledo room
    “Milestones achieved in the treatment of Visceral Leishmaniasis”
    Sponsored by Gilead

    17:30-18:00 Coffee break

    18:00-19:30 Satellite simposium

    Toledo room
    “Major issues in Vector Control”
    Organized and sponsored by WL6, Inesfly and Mundo Sano.
    Chair: Rajib Chowdhury. National Institute of Preventive and Social Medicine (NIPSOM), Bangladesh.
    Co-chair Michael Coleman, LSTM, Liverpool, UK
    · Insecticide resistance in sand flies. Michael Coleman. LSTM, Liverpool, UK
    · Challenges in vector control for the kala-azar elimination and post-elimination era in India. Sridhar Srikantiah, CARE, India
    · Eco-epidemiology and GIS. Daniel Oscar Salomón. Instituto Nacional de Medicina Tropical, Puerto Iguazú, Argentina
    · Climate-change & land use. Guy Hendrickx, Avia GIS, Belgium
    · Inesfly, an innovative method for sand fly control Debashis Gosh, Bangladesh

    16:30-19:30 Poster presentations
    Topics
    4- Early drug discovery. Animal models and genetic susceptibility. Drug resistancemechanisms
    5- Drug development: conventional and alternative. Clinical and experimental therapy in cutaneous and visceral leishmaniasis
    15- Mucocutaneous leishmaniasis, diffuse cutaneous leishmaniasis, post-kala-azar leishmaniasis




    THURSDAY MAY 18TH


    08:30-09:30 Plenary session 2
    Auditorium

    Can VL be eliminated in the Indian subcontinent?
    Conducted by Daniel Argaw. WHO, Geneva, Switzerland
    Panelists:
    · M. Boelaert. Institute of Tropical Medicine, Antwerp, Belgium
    · M. Jamsheed. WHO/SEARO, New Delhi, India
    · A.C. Dhariwal. Ministry of Health and Family Welfare, New Delhi, India
    · A. Be-Nazir. NIPSON, Dhaka, Bangladesh
    · C. Bern. University of California, San Francisco, USA

    09:30-11:00 Parallel sessions

    Auditorium
    (16) T cells response in the protection and pathology of leishmaniasis
    Chair Edgar Carvalho. Universidade Federal da Bahía and FIOCRUZ, Salvador de Bahía, Brazil
    Co-chair Paul Kaye. University of York, York, UK

    16.1. Leishmania-neutrophil crosstalk impacts the T cell response Fabienne Tacchini-Cottier. University of Lausanne, Switzerland

    16.2 Interactions between Leishmania and cells of innate and adaptive immune responses. Claudia Brodskyn. FIOCRUZ, Salvador de Bahia, Brazil

    16.3 Identification of protective Leishmania-specific CD4+ T cells: implications for vaccine design and vaccination strategies against leishmaniasis.
    Jude Uzonna. University of Manitoba, Winnipeg, Canada

    16.4 IL-17 is associated with protection in human visceral leishmaniasis. Om Prakash Singh. Banaras Hindu University, Varanasi, India

    Toledo room
    (17) Diagnosis of dermal leishmaniasis, limitations and challenges
    Chair Elisa Cupolillo. Instituto Oswaldo Cruz, Rio de Janeiro, Brazil
    Co-chair Israel Cruz. FIND, Geneva, Switzerland

    17.1 Exploiting the human anti-alpha-Gal response for the diagnosis of Old World cutaneous leishmaniasis. Alvaro Acosta Serrano. Liverpool School of Tropical Medicine and Hygiene, Liverpool, UK

    17.2 Role of molecular tools in clinical management of cutaneous leishmaniasis: diagnosis, species identification and parasite quantification. Elisa Cupolillo. Instituto Oswaldo Cruz, Rio de Janeiro, Brazil

    17.3 Evaluation of PoC tests for CL diagnosis in Afghanistan. Israel Cruz. FIND, Geneva, Switzerland

    17.4 Minimally invasive microbiopsies: a novel sampling method for identifying asymptomatic potentially infectious carriers of Leishmania donovani. Oscar Kirstein. Hebrew University of Jerusalem, Israel

    Greco room C1-C2
    (18) New vector control measures
    Chair Dia Elnaiem. University of Maryland, Maryland, USA
    Co-chair Alexandra Chaskopoulou. USDA-ARS European Biological Control Lab, Thessaloniki, Greece

    18.1 Experimental strategies for intercepting sand flies to prevent them from reaching and entering homes. Alon Warburg. Hebrew University of Jerusalem, Israel

    18.2 A new approach in the control of Lutzomya longipalpis s.l. in Brazil Reginaldo Brazil. IOC-Fiocruz, Rio de Janeiro, Brazil

    18.3 Novel methods of control of visceral leishmaniasis vectors in East Africa. Dia Elnaiem. University of Maryland, Maryland, USA

    18.4 Integrated vector management for the control of wild sand fly populations associated with animal facilities. Alexandra Chaskopoulou.USDA-ARS European Biological Control Lab, Thessaloniki, Greece

    09:30-11:00 Oral communications sessions

    Greco room D1-D2
    Oral communications session 13
    Chair Antonio Jiménez
    Co-chair Peter Kima?

    Miradero room
    Oral communications session 14
    Chair Montserrat Gállego
    Co-chair Sinval Pinto Brandao Filho


    11:00-11:30 Coffee break

    11:30-13:00 Parallel sessions

    Auditorium
    (19) Molecular basis on virulence and tropism
    Chair David Sacks. NIH, Betehesda, USA
    Co-chair Jean Claude Dujardin. Institute of Tropical Medicine, Antwerp, Belgium
    19.1 Probing the strategies of antimony resistant Leishmania donovani to induce aggresive infection Syamal Roy, Indian Institute of Chemical Biology, Kolkata, India
    19.2 Metastatic leishmaniasis. Nicolas Fasel. University of Lausanne, Switzerland
    19.3 The genetic basis for the natural attenuation of Leishmania donovani Greg Matlashewski. McGill University, Montreal, Canada
    19.4 Immune deviation in human leishmaniasis David Mosser. University of Maryland, Maryland, USA
    Toledo room
    (20) CL treatment and pipeline drugs
    Chair Max Grögl. U.S. Naval Medical Research Unit No. 6, Lima, Peru
    Co-chair Olga Zerpa. Emerson Clinical Research Insitute, Washington, USA

    20.1 Current recommendations for treating CL worldwide. Afif Bensalah. Arabian Golf Univeristy, Bahrein

    20.2 CL treatment: clinical developments. Byron Arana. DNDI, Geneva, Switzerland

    20.3 CL R&D pipeline. Charles Mowbray. DNDI, Geneva, Switzerland

    20.4 Harmonised clinical trial methodologies for CL. Piero Olliaro. WHO/TDR, Geneva, Switzerland

    Greco room C1-C2
    (21) What´s new on reservoirs?
    Chair Jeffrey Shaw. Universidade de Sao Paulo, Sao Paulo, Brazil
    Co-chair Luigi Gradoni. Istituto Superiore di Sanitá, Roma, Italy

    21.1 Updates on reservoirs of American Leishmaniasis. André Roque. Instituto Oswaldo Cruz, Rio de Janeiro, Brazil

    21.2 The role of bats as reservoirs of leishmaniasis. Cáris Maroni Nunes.
    Faculty of Veterinary Medicine, Araçatuba, São Paulo, Brazil

    21.3 Potential reservoirs in Mediterranean leishmaniasis. Ezio Ferroglio. University of Turin, Italy

    21.4 Is Tarim hare a reservoir of desert-type visceral leishmaniasis in Taklamakan basin, Xinjiang, China? KPChang. Rosalint Franklin University, Chicago, USA

    11:30-13:00 Oral communications sessions

    Greco room D1-D2
    Oral communications session 15
    Chair Carlos Muskus
    Co-chair Jose María Alunda

    Miradero room
    Oral communications session 16
    Chair Eugenia Carrillo
    Co-chair Manuel Barral Neto?

    13:00-14:00 Lunch break

    14:00-15:30 Parallel sessions

    Auditorium
    (22) Advances in Immunopathology
    Chair Nancy Saravia. CIDEIM, Cali, Colombia
    Co-chair Ali Mohammadian Mohammad Hussein. Institut Pasteur, Teheran, Iran

    22.1 Pathways involved in the outcome of Leishmania infantum infection. Selma Jeronimo. Universidad Federal do Rio Grande du Norte, Brazil

    22.2 Cytotoxic CD8 T cells in the pathology of leishmaniasis. Philip Scott. University of Pennsylvania, Philadelphia, USA

    22.3 Neutrophil phenotypes in human leishmaniasis. Mary Wilson. University of Iowa, Iowa, USA

    22.4 Leishmania RNA virus-1 is equally distributed among severe and non-severe phenotypes in a prospective cohort of American tegumentary leishmaniasis. Braulio Mark Valencia. Institute of Tropical Medicine Alexander von Humboldt,
    Universidad Peruana Cayetano Heredia, Lima, Peru

    Toledo room
    (23) Physical methods and natural (phyto) products for CL treatment
    Chair: Naomi Aronson. Uniformed Services University, Bethesda, USA
    Co-Chair: Sara Robledo. Universidad de Antioquia, Medellin, Colombia

    23.1 Thermotherapy in the treatment of CL. Naomi Aronson. Uniformed Services University, Bethesda, USA

    23.2 Clinical experience using cryotherapy for CL. Ali Khamesipour. Insitut Pasteur, Teheran, Iran

    23.3 Evaluation of the antileishmanial effects of natural products (plants) extracts. Antonia Franco. Instituto Nacional de Pesquisas da Amazônia, Manaos, Brazil

    23.4 Clinical experience using herbal medicine for CL. Farhad Handjani. Shiraz University, Iran

    Greco room C1-C2
    (24) WHO control Programmes
    Chair José Antonio Ruiz Postigo. WHO, Geneva, Switzerland
    Co-chair Elkhan Gasimov. WHO/EURO, Copenhagen, Denmark

    24.1 Structure, achievements and challenges in leishmaniasis control in the WHO African region. Abate Mulugueta. WHO/AFRO, Addis Ababa, Ethiopia

    24.2 East Mediterranean region. Albis Gabrielli. WHO/EMRO, Cairo, Egypt

    24.3 Leishmaniasis control programme in the WHO European region. Elkhan Gasimov. WHO/EURO, Copenhagen, Denmark

    24.4 Epidemiological analysis of deaths by visceral leishmaniasis in the Americas: challenges for public health. Ana Nilce ElKhouri. WHO/PAHO, Rio de Janeiro, Brazil

    15:00-16:30 Oral communications sessions

    Greco room D1-D2
    Oral communications session 17
    Chair Laia Solano?
    Co-chair Patricia Tavares Veras

    Miradero room (15:00-16:00)
    Oral communications session 18
    Chair Philippe Desjeux
    Co-chair Virginia Iniesta

    15:30-17:00 Oral communications sessions

    Greco room C1-C2
    Oral communications session 19
    Chair Zaida Yadón
    Co-chair Axel Kroeger?

    16:00-17:30 Satellite symposium

    Auditorium
    «Cutaneous Leishmaniasis prevention, diagnosis and management: existing and future tools”
    Sponsored by Sanofi
    Co-chairs:
    · Pierre Buffet. Institut National de Transfusion Sanguine, France
    · Karim Aoun. Institut Pasteur de Tunis, Tunisia
    WHO and PAHO: Overview of available tools for training
    · Jose Antonio Ruiz Postigo. WHO, Switzerland
    Behavior change communication through a comic book in schools in Tunisia’s endemic areas
    · Aida Bouratbine. Institut Pasteur de Tunis, Tunisia
    Newly available support for medical education
    · Pierre Buffet. Institut National de Transfusion Sanguine, France
    An app to aid diagnosis of Leishmaniasis in endemic areas in Colombia
    · Luisa Rubiano, Centro Internacional de Entrenamiento e Investigaciones Médicas, Colombia

    17:30-18:00 Coffee break

    18:00-19:30 Consensus symposium

    Auditorium
    Route Map for Cutaneous Leishmaniasis drugs

    Conducted by Simon Croft, London School of Hygiene and Tropical Medicine and Byron Arana, DNDi
    Panelists: to be defined

    Over the past decades there has been progress in the treatment and pre-clinical development of drugs for visceral leishmaniasis. In contrast, many parts of R & D for cutaneous leishmaniasis have been left behind. One part of the CL pathway has received attention, namely the design and analysis of clinical trials. But where are the new drugs to enter the clinical trials?
    This session will focus on potential routes to take new drugs and treatments from discovery to clinical trials. It willexamine the relevance and use of assays and models for evaluation, the value of PK PD analysis, systemic and topical formulations, and roles for immunomodulatory, combinations and re-purposing. Regulatory issues will also be considered.
    Outcomes will include (i) a consensus document for publication and (ii) an understanding by participants of how better to work together to bring new drugs forward.

    18:00-19:30 Satellite symposium

    Toledo room
    “How to communicate better in leishmaniasis”
    Organized by Mundo Sano and DNDi and sponsored by Mundo Sano.
    Expected Outcome: to deliver an article that could be disseminated in the different journals just before the congress.
    Chair Irene Tato, Mundo Sano
    Co-chair:Jean François Alesandrini, DNDi
    Emilio de Benito. El País. Chair of ANIS, Spanish Association of Health Journalists
    Antonio Calvo Roy. Chair of the AECC, Spanish Association of Scientific Communicators
    Talha Burki. The Lancet, UK
    Verah Okeyo. Daily Nation, Kenya
    · Nora Bär. La Nación, Argentina
    · Franziska Badenschier. European Science Journalists, Germany

    16:30-19:30 Poster presentations
    Topics
    6- Diagnostic methodology in practice and under development. Biomarkers in leishmaniasis
    7- Clinical and experimental immunopathology and pathogenesis
    8- Clinical and experimental prophylactic and therapeutic vaccination. Clinical and experimental immunology


    FRIDAY MAY 19TH


    08:30-09:30 Plenary session 3

    Auditorium
    Conflict and leishmaniasis
    Conducted by Koert Ritmeijer. Médecins Sans Frontières
    Panelists:
    · I. Vélez. PECET, Medellín, Colombia
    · Mounir Lado. IMA World Health, Juba, South Sudan
    · T. Burki. The Lancet
    · Alice Cowley. Mentor, UK

    09:30-11:00 Parallel sessions

    Auditorium
    (25) Population genetics and molecular epidemiology
    Chair Jenefer Blackwell. Cambridge University, UK
    Co-chair Israel Cruz. FIND, Geneva, Switzerland

    25.1 Genome-wide studies of genetic risk factors for human leishmaniasis. Jenefer M Blackwell. Cambridge University, UK

    25.2 Genomics of L. donovani and drug resistance: the roles of cryptic genome diversity. Hideo Imamura. Institute of Tropical Medicine, Antwerp, Belgium

    25.3 Comparative analysis of genetically and phenotypically variable Leishmania donovani hybrids allows to explore their capacity for adaptative evolution. Evi Gouzelou. Institut Pasteur International Network, Paris, France

    25.4 Systematics and population genetics of phlebotomine sand flies and their consequences on the epidemiology of the leishmaniases. Jérôme Depaquit. Université de Reims Champagne Ardenne, Reims, France

    Toledo room
    (26) Advances in Immunotherapy
    Chair Farrokh Modabber. Former WHO/TDR
    Co-chair Abhay Satoskar. Ohio State University, Ohio, USA

    26.1 Host directed therapy. Chris Engwerda. QIMR Berghofer Medical Research Institut, Brisbane, Australia

    26.2 RNA vaccines. Steve Reed. IDRI, Seattle, USA

    26.3 CpG ODN for immunotherapy in CL. Daniela Verthelyi. FDA, Betehesda, USA

    26. 4 Targets for immunotherapy of leishmaniasis. Diane MacMahon-Pratt. Yale University, New Haven, USA

    Greco room C1-C2
    (27) Quantitative studies of Leishmaniasis transmission and control
    Chair Orin Courtenay. University of Warwick, UK
    Co-chair Sake de Vlas. Erasmus University, Rotterdam, Netherlands

    27.1 Longitudinal study of transmission in households with visceral leishmaniasis, asymptomatic infections and PKDL in Bihar, India. Greg Matlashewski. McGill University, Montreal, Canada

    27.2 Spatial clustering of visceral leishmaniasis, asymptomatic infection and PKDL in Bangladesh. Lloyd Chapman, University of Warwick, UK

    27.3 Community coverage with insecticide-impregnated dog collars protects against human clinical VL in NW Iran. Orin Courtenay. University of Warwick, UK

    27.4 Elimination of visceral leishmaniasis on the indian subcontinent: a comparison of predictions from three transmission models. Epke Le Rutte. Erasmus MC, University Medical Center Rotterdam, The Netherlands

    09:30-11:00 Oral communications sessions

    Greco room D1-D2
    Oral communications session 20
    Chair Simona Stager
    Co-chair Jordi Alberola

    Miradero room
    Oral communications session 21
    Chair Juan AntonionCastillo
    Co-chair Yusuf Ozbel

    11:00-11:30 Coffee break

    11:30-13:00 Parallel sessions

    Auditorium
    (28) Bioimaging
    Chair Geneviève Milon. Institut Pasteur, Paris, France
    Co-chair Silvia Uliana. Universidade de Sao Paulo, Brazil

    28.1 A drug discovery platform against visceral leishmaniasis, moving forward in vivo preclinical models Rosa M. Reguera. Universidad de León, León, Spain

    28.2 Imaging to better understand host-parasite interaction. Lynette Beattie, University of Queensland, Australia

    28.3 Measuring leishmania growth and physiology in vivo at the single cell level using imaging mass spectrometry. Malcolm McConville. University of Melbourne, Melbourne, Australia

    Toledo room
    (29) MCL and DCL
    Chair Alejandro Llanos-Cuentas. Universidad Cayetano Heredia, Lima, Peru
    Co-chair Felix Tapia. Universidad Central, Caracas, Venezuela

    29.1 Host determinants in the outcome of treatment of dermal leishmaniasis. María Adelaida Gómez. CIDEIM, Cali, Colombia

    29.2 Clinical Characteristics and Treatment Options for MCL, DCL and DL patients.
    Paulo Roberto Lima Machado. Fundação de Medicina Tropical do Amazonas, Manaus, Brazil

    29.3 The natural history of Leishmania (Viannia) infection: metastasis and persistent infection. Nancy Saravia. CIDEIM, Cali, Colombia

    29.4 Immunological mechanisms of MCL and DCL. Felix Tapia. Universidad Central, Caracas, Venezuela

    Greco room C1-C2
    (30) Leishmaniasis vaccine pipeline
    Chair Javier Moreno. ISCIII, Madrid, Spain
    Co-chair Hira Nakhasi. FDA, Bethesda, USA

    30.1 Killed vaccines. Ali Khamesipour. Insitute Pasteur,Teheran , Iran

    30.2 Vaccines that promote CD8+ T cell responses. Paul Kaye. University of York, York, UK

    30.3 From mouse to man: development of a candidate visceral leishmaniasis vaccine. Rhea Coler. IDRI, Seattle, USA

    30.4 Live attenuated vaccines for leishmaniasis. Hira Nakhasi. FDA, Bethesda, USA

    11:30-13:00 Oral communications sessions

    Greco room D1-D2
    Oral communications session 22
    Chair Dolores González-Pacanowska
    Co-chair Eric Chatelain

    Miradero room
    Oral communications session 23
    Chair Daniel Salomon?
    Co-chair Elizabeth Rangel?

    13:00-14:00 Lunch break

    14:00-15:30 Parallel sessions

    Auditorium
    (31) Delivery systems for drugs and vaccines
    Chair Ijeoma Uchegbu. Nanomerics Ltd, UK
    Co-Chair Anabela Cordeiro. Universidade do Porto, Porto, Portugal

    31.1 Translational studies - pharmacological beneficial organ targeting via the oral route Ijeoma Uchegbu. Nanomerics Ltd, UK

    31.2 Anti microbial peptide based immunotherapy: various approaches to control leishmaniasis. Sima Rafati. Institute Pasteur, Iran

    31.3 Virosomal platform as delivery system for Leishmaniasis vaccine. Epifanio Fichera. Ednabiotech, Catania, Italy

    Toledo room
    (32) Drug Resistance
    Chair Alicia Ponte Sucre. Universidad Central de Venezuela, Caracas, Venezuela
    Co-chair Barbara Papadopoulou. University Laval, Québec, Canada

    32.1 What are we talking about when we mention resistance? Rogelio López-Vélez. Hospital Universitario Ramón y Cajal, Madrid, Spain

    32.2 Resistance to drug combination therapy in Leishmania. Francisco Gamarro.
    Instituto de Parasitología y Biomedicina López-Neyra, Granada, Spain

    32.3 Molecular epidemiology of Leishmania donovani: the many roads to drug resistance. Jean-Claude Dujardin. Institute of Tropical Medicine, Antwerp, Belgium

    32.4 The molecular basis of amphotericin B resistance in Leishmania. Michael Barrett. Roslyn Institute, Glasgow, UK

    Greco room C1-C2
    (33) Canine leishmaniosis: where do we stand?
    Chair Bruno Travi. University of Texas Medical Branch, Galveston, USA
    Co-chair Francisco Rojo. Universidad de Leon, Leon, Spain

    33.1 The utility of Rapid Diagnostic Tests in the clinic and in the field.
    Bruno Travi. University of Texas Medical Branch, Galveston, USA

    33.2 The impact of treatment on dog infectiousness. Guadalupe Miró. Universidad Complutense de Madrid, Madrid, Spain

    33.3 Are prevention and control strategies working? Filipe Dantas-Torres. Aggeu Magalhães Research Centre-FIOCRUZ, Recife, Brazil

    33.4 New marker for the diagnosis of visceral leishmaniosis in asymptomatic dogs. Anabela Cordeiro. Universidade do Porto, Porto, Portugal

    15:00-16:30 Oral communications sessions

    Greco room D1-D2
    Oral communications session 24
    Chair Maribel Jiménez
    Co-chair Rajib Chowdhury

    Miradero room (15:00-16:00)
    Oral communications session 25
    Chair Pilar Aparicio
    Co-chair Johan van Griensven?

    15:30-17:00 Oral communications sessions

    Greco room C1-C2
    Oral communications session 26
    Chair Clemencia Ovalle?
    Co-chair Francisco Bolás

    16:00-17:30 Satellite symposium

    Toledo room
    “Research in Leishmania vaccines”
    Sponsored by Leti
    · Ribosomal proteins for a human leishmaniasis pan vaccine: beyond Protein Q. Marta Román. LETI
    · Toll like receptors (TLR) in canine leishmaniosis: role in disease and use on prevention. Laia Solano. Universidad Autónoma Barcelona
    · Safety Multicenter post authorization pilot study on LetiFend, the new recombinant vaccine against canine leishmaniosis. Guadalupe Miró. Universidad Complutense Madrid


    16:00-19:30 Consensus symposium

    Auditorium
    Advocating for the future
    Conducted by Jorge Alvar, chair of Worldleish 6
    Minister of Health of Colombia
    Ministers of Health from several endemic countries to be confirmed
    Mercedes Tatay, International Medical Secretary of Médecins Sans Frontières
    Bernard Pécoul, Executive director, DNDi


    17:30-18:00 Coffee break

    18:00-19:30 Satellite symposium

    Toledo room
    “Fuenlabrada outbreak”
    Sponsored by Dirección General de Salud Pública Comunidad de Madrid and Colegio Oficial de Veterinarios de Madrid
    Chair Juan Martínez Hernández. Director General de Salud Pública de la Comunidad de Madrid
    Co-chair Richard Ashford, Former Professor at Liverpool School of Tropical Medicine, UK
    · Epidemiological aspect of the outbreak. María Ordobás. Servicio de Epidemiología, Comunidad de Madrid.
    · Clinical aspects. Juan Victor San Martin. Hospital Universitario Fuenlabrada, Madrid, Spain
    · Sand fly and reservoir studies. Ricardo Molina ISCIII, Madrid, Spain
    · Environmental control actions. Jesús Carpintero Hervás. Consejería de Medio Ambiente, Administración local y Ordenación del territorio, Comunidad de Madrid, Spain
    · Final remarks and presentation of the book “Brote de leishmaniasis en Fuenlabrada y otros municipios de la Comunidad de Madrid: el papel de las liebres y los conejos como resevorios”. Felipe Vilas. Dirección General de Salud Pública. Comunidad de Madrid

    16:30-19:30 Poster presentations
    Topics
    9- Epidemiology. Asymptomatic infection
    10- Leishmania-HIV co-infection
    12- Reservoirs
    13- Operational research
    14- Control programs. National and international funding organizations


    SATURDAY MAY 20TH


    08:30-09:30 Plenary session 4

    Auditorium
    Access to treatment
    Conducted by Margriet den Boer, Médecins Sans Frontières
    Panelists:
    · B. Pécoul. DNDi, Geneva, Switzerland (hay que poner este nombre debajo de panelists, no a continuación para que se vea que son 4 personas)
    · R. Sebbag Former Vice President Access to Medicines, Sanofi-Aventis
    · JA Ruiz-Postigo. WHO/Leishmaniasis programme, Geneva, Switzerland
    · Nirmal Kumar Ganguly. Visiting professor of eminence Translational Health Science & Technology Institute NCR Biotech Science Cluster, Faridabad, India

    09:30-11:00 Parallel sessions DECIDIR LAS SALAS DEFINITVAS DE LAS TRES SESIONES

    Auditorium
    (34) Challenges on implementation and development of clinical trials
    Chair Nathalie Strub-Wourgaft. DNDi, Geneva, Switzerland
    Co-chair Jane Mbuy. KEMRI, Nairobi Kenya

    34.1 Methodology and study design. Vishal Goyal. DNDI, India

    34.2 Good clinical practices. Varalakshmi Elango. Former WHO/TDR

    34.3 From clinical trials to access. Nathalie Strub-Wourgraft. DNDi, Geneva, Switzerland

    34.4 Progress of approval of clinical trials. NO tenemos reemplazo todavia,

    Greco room D1-D2 room
    (35) Students and Masters talking out of the box

    Conducted by Graeme Bilbe, DNDi Geneva and SteveReed, IDRI-Seattle
    Panelists:
    Rob Davidson, Northwick Park Hospital, London
    Caryn Bern, California University
    Franziska Badenschier. European Union of Science Journalists´Associations, Germany

    Falta por incluir:
    Joana Pissarra. Euroleish student
    Temmy (apellido?)

    Greco room C1-C2
    (36) Platforms for research and control
    Chair Monique Wasunna. DNDi, Nairobi, Kenya
    Co-chair Jorge Alvar. DNDi, Geneva, Switzerland

    36.1 The Leishmaniasis East African Platform: contributing to strengthening clinical trial capacity, treatment and control of visceral leishmaniasis in Eastern Africa. Asrat Hailu. University of Addis Ababa, Addis Ababa, Ethiopia

    36.2 Leishmaniasis research network (RedLeish): experience in Latin America. Joelle Rode. DNDi, Rio de Janeiro, Brazil

    36.3 Building a joint effort to optimally assess the efficacy of visceral leishmaniasis therapies: a VL data repository and network. Philippe Guerin. Oxford University, Oxford, UK

    36.4 Kalacore-Bi regional support for the control and elimination of visceral leishmaniasis in Africa and Asia: developing an integrated approach to implementation and research. Simon Croft. London School of Hygiene and Tropical Medicine, London, UK

    09:30-11:00 Oral communications sessions

    Miradero room
    Oral communications session 27
    Chair Mousab Elhag
    Co-chair Margriet den Boer

    11:00-11:30 Coffee break

    08:30-12:00 Satellite symposium

    Toledo room
    LeishVet
    Sponsored by Bayer
    Chair: Jorge Alvar, DNDi Geneva, Switzerland
    Co-chair: Guadalupe Miró, Universidad Complutense Madrid, Spain
    · Introduction to the Symposium and to LeishVet. Guadalupe Miró
    · Benefits of a One Health approach to leishmaniosis. Michael Day. University of Bristol, UK
    · Canine leishmaniosis in South America and in the Mediterranean basin (including other species of Leishmania infecting dogs). Luis Cardoso. Universidade de Trás-os-Montes e Alto Douro, Vila Real, Portugal
    · Emergence of canine leishmaniosis in new regions; is development in non-endemic areas a risk? Patrick Bourdeau. Ecole Nationale Vétérinaire, Agroalimentaire et de l´Alimentation, Nantes-Atlantique (ONIRIS), Nantes, France
    · Canine immunity to Leishmania infection: moving towards successful immunotherapy. Christine Petersen. University of Iowa, College of Public Health, USA
    · Lessons learned regarding feline leishmaniosis over the last decade (including gaps in knowledge). Maria Grazia Pennisi. Università di Messina, Messina, Italy
    Chair Guadalupe Miró
    Co-chair Gad Baneth, Hebrew University, Rehovot, Israel
    · Diagnostic approaches to canine leishmaniosis in the era of vaccines. Laia Solano-Gallego. Universidad Autónoma de Barcelona
    · Current drug therapy and resistance in canine leishmaniosis. Gad Baneth
    · Use of immunosuppressive drugs in Leishmania infected dogs: how to minimize risks. Lluis Ferrer. Tufts Cummings School of Veterinary Medicine, Massachusets, USA
    · Vaccines against canine leishmaniosis – advantages and pitfalls. Gaetano Oliva. Università di Napoli, Napoli, Italy
    · Best canine leishmaniosis prevention strategies/measures in different settings. Guadalupe Miró

    11:30-12:00 Awards

    Auditorium
    Photography contest
    Plos collection papers
    Tributes:
    · Prof CP Thakur by Dr.Suman Rijal
    · Prof AM El Hassan by Dr. Ahmed Musa
    Homage:
    · Prof Rioux by Dr. I Velez


    12:00-12:45 Closing conference

    Auditorium
    “War and peace: health indicators”
    Alejandro Gaviria. Minister of Health, Colombia

    12:45-13:15 Closing remarks

    Auditorium

    COMMITTEES

    Organizing

    Committee
    arrow_forward

    WORLD LEISH Scientific

    Committee
    arrow_forward

    Ad hoc Scientific

    Committee
    arrow_forward

    Spanish Scientific

    Committee
    arrow_forward

    Organizers Scientific

    Committee (DNDi, ISCIII)
    arrow_forward

    PLOS COLLECTION

    To accompany this major event, the WL6 Scientific Community, in partnership with PLOS Neglected Tropical Diseases and PLOS ONE, call for research papers to be submitted for consideration for a WorldLeish-6 Collection.
    http://collections.plos.org/worldleish6#section-world-leish-6 ►

    The WL6 Scientific Committee has identified a series of major topics that will provide the background to the main scientific sessions during the congress, and the organizers would like to celebrate a Jubilee of Leishmaniasis by inviting the scientific community to submit papers addressing "hot" topics within the major areas selected.

    Drs. Jorge Alvar and Javier Moreno (chair and co-chair of the WL-6 conference respectively) will act as the PLOS Collection Curators and as such will choose the articles to be included alongside their accompanying editorial.

    Submissions can be made to PLOS Neglected Tropical Diseases, PLOS Pathogens ► or PLOS ONE ► . Those articles which are accepted for publication will be included in a rolling collection on Leishmaniasis – papers will not be held for coordinated publication, as PLOS and the WL6 Scientific Committee do not want to delay the release of important research in this field.

    From those papers accepted to the collection, DNDi will award prizes to 20 researchers at WL6. The WL6 Scientific Committee will decide which papers receive the prizes, which are intended to help fund the publication of future research in this field.

    The WL6 leishmanisasis collection was launched in December 2016 and is ongoing http://collections.plos.org/worldleish6#section-world-leish-6 ►

    For more information, read the PLOS Collections Blog ►, or contact collections@plos.org

    REGISTRATION and ACCOMMODATION

    We would like to inform you that online registration system is closed. If you want to register, you can do it on-site, during the congress dates, at the Registration Support Office which will be placed in the entrance of the venue.

    REGISTRATION FEES

    The early registration fee has been extended to February 20, 2017
    Registration
    after 20/02/2017
    Last minute registration
    after 16/05/2017
    Regular Registration 400 € 490 €
    Students* 230 € 335 €
    SPECIAL FEE for LeishVet Simposium- SATURDAY*** 121 € 121 €
    Accompanying person** 250 € 250 €
    Tapas Dinner -Regular ticket 40€ 40€
    Tapas Dinner - Vegetarian Option 40€ 40€
    21% VAT included
    Regular Registration
    Registration
    after 20/02/2017
    400 €
    Last minute registration
    after 01/05/2017
    490 €
    SPECIAL FEE for LeishVet Simposium- SATURDAY***
    Registration
    after 20/02/2017
    121 €
    Last minute registration
    after 01/05/2017
    121 €
    Students*
    Registration
    after 20/02/2017
    230 €
    Last minute registration
    after 01/05/2017
    335 €
    Accompanying person**
    Registration
    after 20/02/2017
    250 €
    Last minute registration
    after 01/05/2017
    250 €
    21% VAT included
    * Student fee applies to full time students and a copy of the University registration must be emailed to the Technical Secretariat registration@worldleish2017.org Please take into account that Postdoct students and PhD candidates with an income are not considered students, even though work is conducted at a University.
    ** Accompanying person registration doesn’t include access to sessions or lectures.
    ***this special fee includes one day entrance to the LeishVet Symposium, which will take place on May 20, Saturday

    Tickets for the Tapas Dinner are now available at the congress website.
    Dinner will take place on May 18th at the San Agustín Market, at 20:30.
    You can choose between a regular tapas menu and a vegetarian option.
    As the space for the dinner is limited, we recommend you buy your ticket in advance through the website.

    San Agustín Market Address:
    Cuesta Águila, 1-3, 45001 Toledo.
    www.mercadodesanagustin.com

    You will be provided with a ticket per tapa: 6 tapas, 1 dessert and 1 drinks per person are included in the price. Don’t forget to bring your tickets to the dinner because the tickets will be needed while you are ordering the tapas.
    Tapas dinner price: 40 € (VAT included)

    Purchase your ticket



    REGULAR REGISTRATION FEE INCLUDES

    - Admittance to all lectures
    - Congress bag
    - Final Programme
    - Daily coffee breaks
    - Welcome reception
    - Certificate of attendance
    - Abstracts book
    Register now

    PAYMENT

    Registrations will not be processed without payment. Full payment in euros should be received before the corresponding deadline; otherwise, the preferential rate will not be granted.


    Credit card

    Payment by credit card is preferred. For online registration please log on the website. It is advisable for the registrant, prior to registering, to check with their credit card provider or bank, since many debit or credit cards have some limitations with regards to international transactions, require a previous authorization for the payment to be made, or the like.

    Bank transfer

    Account holder: GEYSECO S.L.
    Bank account details: IBAN ES7820386161126000036100
    SWIFT: CAHMESMMXXX
    Bankia
    C/ Ramon Llull, 3
    46021 Valencia- Spain
    Participants paying by bank transfer are requested to send a copy of the bank transfer to the organizing secretariat by fax or by e-mail.

    REGISTRATION CANCELLATION POLICIES

    Refund of registration fees -30% administrative charge will be granted if the cancellation is notified in written to GRUPO GEYSECO S.L. prior until March 1, 2017. After this date, the refund can NOT be returned for cancellation. All refunds will be paid after the congress.

    HOTEL BOOKING CANCELLATION POLICIES

    Any modification or cancellation in hotel bookings has to be notified in writing to the organizing secretariat prior to March 1, 2017. 30% administrative charge will be applied for any modification or cancellation. After this date, no modification is possible and no refund can be made for cancellations. All refunds will be made after the congress. Hotel booking will not be accepted without corresponding payment
    For more information, contact registration@worldleish2017.org

    ACCOMMODATION

    Hotel Cigarral el bosque 5*

    C/ Carretera de Navalpino 49, Toledo
    2,1km from the Venue
    play_arrow

    Hotel Abad Toledo 3*

    C/ Real del Arrabal, 1, Toledo
    350m from the Venue
    play_arrow

    Hotel Carlos V 3*

    C/ Plaza Horno Magdalena s/n, Toledo
    350m from the Venue
    play_arrow

    Hotel Pintor El Greco 4*

    C/ Alamillos del tránsito, 13 - Toledo
    1km from the Venue
    play_arrow

    Hotel Beatriz de Toledo 4*

    C/ Concilios de Toledo s/n - Toledo
    4,3km from the Venue
    play_arrow

    Hotel San Juan de los Reyes 4*

    C/ Reyes Católicos, 5 - Toledo
    1,2km from the Venue
    play_arrow

    Hotel NH Hesperia 4*

    C/ Marqués de Medigorría,. 8- 12, Toledo
    1,1km from the Venue
    play_arrow

    Hotel Eurostars 4*

    C/ Pseo. San Eugenio, sn - Toledo
    1,8km from the Venue
    play_arrow

    Hotel AC Toledo 4*

    C/ Ctra. De Circunvalación, 15 - Toledo
    2,6km from the Venue
    play_arrow

    Hostal Toledo

    Avda. de Castilla la Mancha, 30, 45003, Toledo
    1,7km from the Venue
    play_arrow

    Hotel Alfonso VI 4*

    C/ Cuesta de los Capuchinos, 2, 45001, Toledo
    700m from the Venue
    play_arrow

    Hostal Palacios

    C/Navarro Ledesma, 1, 45001, Toledo
    600m from the Venue
    play_arrow

    Hotel Mayoral 3*

    Avda. de Castilla la Mancha, 3, 45003, Toledo
    900m from the Venue
    play_arrow

    Hotel María Cristina 3*

    C/ Marqués de Mendigorria, 1, 45003, Toledo
    1,1km from the Venue
    play_arrow

    Hostal Alfonso XII

    C/ Alfonso XII, 18, 45002, Toledo
    800m from the Venue
    play_arrow

    Hotel Toledo Imperial 3*

    C/ Horno de los bizcochos, 5, 45001, Toledo
    400m from the Venue
    play_arrow

    Hotel Casona de la Reyna 3*

    C/Carreras de San Sebastián, 26, 45002, Toledo
    1,2km from the Venue
    play_arrow

    Hotel Real de Toledo 3*

    C/Real del Arrabal, 4, 45003, Toledo
    400m from the Venue
    play_arrow

    Venue

    Toledo Conference Centre El Greco

    Calle Venancio González, 24, 45001 Toledo

    The Toledo Congress Centre is just 70 km from Madrid (Spain).
    It is the perfect setting for your events, right in the historical centre of Toledo.

    PLANE

    The nearest airport to Todelo is Madrid Barajas International Airport (MAD).  Toledo it is very close to Madrid (70 Km) and Barajas International Airport (80 Km).

    Driving from Madrid to Toledo

    In just 50 min. you can get to Toledo by motorway from Madrid Barajas International Airport, taking the M-40 or A-42 (Highway Toledo). GPS: 39.861988º N , 4.017735º W.

    BUS

    Buses Madrid-Toledo-Madrid run every 30 minutes daily with a journey time of 55 minutes. Check the schedule here For a direct bus from Madrid Barajas International Airport to Toledo, consult
    BUY

    TRAIN

    Twenty-two fast trains (AVE) daily link Toledo with Madrid (Puerta de Atocha) in just 25 minutes, communicating with the other national fast speed lines and international rail lines.

    Sponsors



    DIAMOND PLUS SPONSOR

    GOLD SPONSOR

    SILVER SPONSOR

    BRONZE SPONSOR

    SPONSORS





    For more information about sponsorship options, including collaboration with the scholarship programme, please contact us sponsors@worldleish2017.org

    100 STUDENTS INITIATIVE PROGRAMME

    Please click here ► to see the list of selected candidates

    In order to make the WorldLeish 6 Congress as accessible as possible to people from resource-limited settings, and in a bid to support the professional development of a new generation of scientists from endemic countries in the fight against leishmaniasis, the 100 STUDENTS INITIATIVE PROGRAMME will provide financial assistance to help people who would otherwise be unable to attend because of travel and registration costs.

    Even though every attempt will be made to assist as many applicants as possible, we regret that there were only a limited amount of scholarships available. The programme will support the costs for between 80 and 120 eligible participants from all continents, particularly those coming from low- and middle-income countries.

    Successful applicants will receive financial support for travel and/or accommodation costs and will also benefit from registration to the Congress.

    Am I eligible?

    Those eligible for 100 STUDENTS INITIATIVE PROGRAMME Initiative include students and young scientists (less than 35 years of age) whose abstracts are accepted as first author for WL6 and that can demonstrate the need for financial support in order to attend the Congress.

    How should I apply?

    Candidates are welcome to apply through the Congress secretariat by email (secretariat@worldleish2017.org), attaching the following documents:

    Curriculum vitae: The CV should be 2 pages maximum and include qualifications, key papers or research topic, main supervisor (if applicable) and title and number of accepted abstract (this number is given automatically when the abstract submission process is completed).

    Students: Students must prove their status by providing a copy of a certificate issued by the institution where they are enrolled. Post-doc students must prove there is no contractual relationship with their institutions in order to benefit from a student status.

    Motivation letter: A one page document where the applicant should explain the reasons why he/she hopes to attend the congress, how their organisation will benefit from their attendance and demonstrate the financial need.

    Letter of recommendation: This is a one-page recommendation letter written by the research supervisor, mentor or teacher. This letter must be reviewed and approved by the candidate´s institution.

    How is my application reviewed?

    A 100 STUDENTS INITIATIVE PROGRAMME review committee composed of members from DNDi and ISCIII, the two institutions organizing the WL6 Congress, will review applications. The WL6 chair and co-chair, the WL6 organizing committee, the event coordinator and the directors of DNDi´s regional offices in Asia, Latin America and Africa will be part of the committee.
    Candidates will be selected based on their professional career, country of residence and/or work, institution or organization funding the candidate´s research, candidate´s political and social context and personal circumstances. A balanced gender and geographical distribution of grants is a key element of 100 STUDENTS INITIATIVE programme.

    What is the deadline?

    Applications will open on 15th October 2016 and end on 15th January 2017 Selected candidates will be contacted individually by the end of January 2017. Their names and countries will be published as part of the Congress information pack.

    THANK YOU. NO MORE APPLICATIONS ARE BEING ACCEPTED

    JUBILEE

    Leishmaniasis Jubilee Activities have been organized around the congress by the WorldLeish6 Organizing Committee.Four activities have been scheduled which aim to bring a greater awareness of leishmaniasis to the general public.

    The WorldLeish6 PLOS Collection is an initiative that was established in May 2016. The main objectives are to share research and accelerate open access publications related to the main topics of the congress.  The collection will bring together approximately 50 papers related to WorldLeish6 from PLOS One, PLOS NTDs and PLOS Pathogens as well as other open access journals.  From the papers thatare accepted into the collection, DNDi will award prizes to researchers at WorldLeish6.  The prizes are intended to help fund the publication of future research in this field.  (visit the collection at LINK )

    Photography Contest and Exhibition will be on display at the Cultural Center ‘San Marcos’, in Toledo, from May 17th - May 20th, 2017. Seventy-five leishmaniasis-related photographs from congress participants have been selected. In addition, a book featuring these images will be printed and distributed to all those attending the congress. (See rules and terms of reference at Photography-LEISH.PDF )
     
    A Special Session at the Spanish Royal Academy of Medicine Madrid (RANM) on “Violence and Leishmaniasis” will be broadcasted on May 22nd, 2017 from 18:00 - 20:00 to all Spanish speaking countries in the Americas.  The epidemics in South Sudan, Colombia, Middle East, and Syrian refugee camps will be reviewed in the context of war and civil unrest. This Special Session will be chaired by Prof G Piédrola, a member of the RANM, and Dr J Alvar, President of WorldLeish6 and correspondent member of the RANM. Dr J Postigo (WHO),Dr K Ritmeijer (MSF), Prof Iván DVélez (PECET, Colombia), and Dr A Cowley (Mentor Initiative) will be speaking at the event.

    An Exhibition on Leishmaniasis at the National Natural History Museum in Madrid will display simple diagrams, photographs, and 3D models to explain the biology of Leishmania and the sandfly.  The exhibition will also feature an explanation of the biological life cycle of leishmaniasis and an informative article on “Leishmaniasis beyond your pet” published by Dr J Alvar in NaturalMente, the museum’s online, open access journal.  The display will be rolled out in various Spanish provinces for several months following the congress.